{"DataElement":{"publicId":"2783887","version":"1","preferredName":"Specimen Histologic Type Type HistologicType","preferredDefinition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:Refers to the type of tissue in which a tumor originated._A subdivision of a particular kind of thing._The type of histologic finding","longName":"2783122v1.0:2783523v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2783122","version":"1","preferredName":"Specimen Histologic Type Type","preferredDefinition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:Refers to the type of tissue in which a tumor originated._A subdivision of a particular kind of thing.","longName":"2782834v1.0:2223243v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2782834","version":"1","preferredName":"Specimen Histologic Type","preferredDefinition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.:Refers to the type of tissue in which a tumor originated.","longName":"C19157:C61478","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specimen","conceptCode":"C19157","definition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histologic Type","conceptCode":"C61478","definition":"Refers to the type of tissue in which a tumor originated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5691B5F0-75E0-74BB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-10","endDate":null,"createdBy":"UMLLOADER_CATISSUE","dateCreated":"2008-09-10","modifiedBy":"ONEDATA","dateModified":"2008-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223243","version":"1","preferredName":"Type","preferredDefinition":"A subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F629F5E5-DE63-1DFD-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5691EBDD-19EF-37DA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-10","endDate":null,"createdBy":"UMLLOADER_CATISSUE","dateCreated":"2008-09-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"9/28/10 Released for use in caTissue Suite version 1.1 and/or 1.2 per owners direction","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2783523","version":"1","preferredName":"HistologicType","preferredDefinition":"The type of histologic finding","longName":"2783523v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"java.lang.String","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Squamous Cell Carcinoma","valueDescription":"Squamous Cell Carcinoma","ValueMeaning":{"publicId":"2567412","version":"1","preferredName":"Squamous Cell Carcinoma","longName":"2567412","preferredDefinition":"A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Squamous Cell Carcinoma","conceptCode":"C2929","definition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D461-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A98887-39AA-9A11-E040-BB89AD434E3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Splenic Marginal Zone Lymphoma","valueDescription":"splenic marginal zone B-cell lymphoma","ValueMeaning":{"publicId":"2579748","version":"1","preferredName":"splenic marginal zone B-cell lymphoma","longName":"2579748","preferredDefinition":"A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  The patients present with splenomegaly and the clinical course is indolent.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Splenic Marginal Zone Lymphoma","conceptCode":"C4663","definition":"A B-cell non-Hodgkin lymphoma composed of small lymphocytes which surround and replace the splenic white pulp germinal centers.  It involves the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.  When lymphoma cells are present in the peripheral blood, they are usually, but not always, characterized by the presence of short polar villi. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0491-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-15","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-15","modifiedBy":"CAMPBELB","dateModified":"2007-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A98887-39BF-9A11-E040-BB89AD434E3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Solitary Plasmacytoma of Bone","valueDescription":"Solitary Osseous Plasmacytoma","ValueMeaning":{"publicId":"2838848","version":"1","preferredName":"Solitary Osseous Plasmacytoma","longName":"2838848","preferredDefinition":"A localized clonal (malignant) plasma cell infiltrate in the bone without peripheral blood involvement.  The most commonly affected bones are the vertebrae, ribs, skull, pelvis and femur.  X-rays examination reveals a solitary lytic lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solitary Plasmacytoma of Bone","conceptCode":"C7812","definition":"A localized malignant neoplasm that arises in the bone. It is composed of clonal (malignant) plasma cells forming a tumor mass. The most commonly affected bones are the vertebrae, ribs, skull, pelvis, and femur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A98887-39CD-9A11-E040-BB89AD434E3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A98887-39E6-9A11-E040-BB89AD434E3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Superficial Spreading Melanoma","valueDescription":"Superficial Spreading Melanoma","ValueMeaning":{"publicId":"2581144","version":"1","preferredName":"Superficial Spreading Melanoma","longName":"2581144","preferredDefinition":"A type of melanoma that typically occurs in light-skinned individuals ranging in age from young adults to the elderly. Risk factors include extensive sun exposure during childhood, a family history of melanoma, and the presence of dysplastic nevi. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low-CSD Melanoma","conceptCode":"C9152","definition":"A type of melanoma that typically occurs in light-skinned individuals ranging in age from young adults to the elderly.  Risk factors include extensive sun exposure during childhood, a family history of melanoma, and the presence of dysplastic nevi.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A05-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"DWARZEL","dateModified":"2006-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A98887-39FF-9A11-E040-BB89AD434E3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Subependymoma","valueDescription":"Subependymoma","ValueMeaning":{"publicId":"2578710","version":"1","preferredName":"Subependymoma","longName":"2578710","preferredDefinition":"Subependymoma (WHO grade I) is a benign, slow growing neoplasm which is typically attached to a ventricular wall. It is composed of glial tumor cell clusters embedded in an abundant fibrillary matrix with frequent microcystic change. Some lesions have the histological features of both subependymoma and ependymoma. It is often detected incidentally and has a very favorable prognosis. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subependymoma","conceptCode":"C3795","definition":"A benign, slow growing neoplasm which is typically attached to a ventricular wall. It is composed of glial tumor cell clusters embedded in an abundant fibrillary matrix with frequent microcystic change. Some lesions have the histological features of both subependymoma and ependymoma. It is often detected incidentally and has a very favorable prognosis. (Adapted from WHO.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0083-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A98887-3A0A-9A11-E040-BB89AD434E3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","valueDescription":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","ValueMeaning":{"publicId":"2838852","version":"1","preferredName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","longName":"2838852","preferredDefinition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subcutaneous Panniculitis-Like T-Cell Lymphoma","conceptCode":"C6918","definition":"A cytotoxic primary cutaneous T-cell lymphoma. Recent studies suggest there are at least two groups of subcutaneous panniculitis-like T-cell lymphomas, each with distinct histologic features, immunophenotypic profile, and prognosis. One group has an alpha/beta, CD8 positive phenotype, involves only subcutaneous tissues, and usually has an indolent clinical course. The second group has a gamma/delta phenotype, is CD8 negative, often co-expresses CD56, is not confined to the subcutaneous tissues, and usually has a poor prognosis. In the recent WHO-EORTC classification, the term subcutaneous panniculitis-like T-cell lymphoma is reserved for cases with an alpha/beta, CD8 positive phenotype. Cases with a gamma/delta phenotype are included in the group of cutaneous gamma/delta T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A98887-3A15-9A11-E040-BB89AD434E3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A98887-3A2E-9A11-E040-BB89AD434E3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Teratoma - Mature","valueDescription":"Mature Teratoma","ValueMeaning":{"publicId":"2838857","version":"1","preferredName":"Mature Teratoma","longName":"2838857","preferredDefinition":"A teratoma which may be cystic; it is composed entirely of well differentiated, adult-type tissues, without evidence of fetal-type tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mature Teratoma","conceptCode":"C9015","definition":"A teratoma which may be cystic; it is composed entirely of well differentiated, adult-type mature tissues, without evidence of fetal-type immature tissues (grade 0 teratoma).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A98887-3A3C-9A11-E040-BB89AD434E3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A98887-3A55-9A11-E040-BB89AD434E3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"T-Cell Prolymphocytic Leukemia","valueDescription":"T-Cell Prolymphocytic Leukemia","ValueMeaning":{"publicId":"2838858","version":"1","preferredName":"T-Cell Prolymphocytic Leukemia","longName":"2838858","preferredDefinition":"An aggressive T-cell leukemia, characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Prolymphocytic Leukemia","conceptCode":"C4752","definition":"An aggressive T-cell leukemia, characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A98887-3A5F-9A11-E040-BB89AD434E3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A98887-3A78-9A11-E040-BB89AD434E3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"T-Cell Large Granular Lymphocytic Leukemia","valueDescription":"T-Cell Large Granular Lymphocyte Leukemia","ValueMeaning":{"publicId":"2590775","version":"1","preferredName":"T-Cell Large Granular Lymphocyte Leukemia","longName":"2590775","preferredDefinition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Large Granular Lymphocyte Leukemia","conceptCode":"C4664","definition":"A T-cell peripheral neoplasm characterized by a persistent (>6 months) increase in the number of peripheral blood large granular lymphocytes, without a clearly identified cause. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F6CF08-5979-36DF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A98887-3A8C-9A11-E040-BB89AD434E3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Systemic Mastocytosis With Associated Clonal/Hematologic Non-Mast-Cell Lineage Disease","valueDescription":"Systemic Mastocytosis with Associated Clonal Hematological non-Mast-Cell Lineage Disease","ValueMeaning":{"publicId":"2838860","version":"1","preferredName":"Systemic Mastocytosis with Associated Clonal Hematological non-Mast-Cell Lineage Disease","longName":"2838860","preferredDefinition":"A disorder characterized by systemic infiltration of internal organs by aggregates of neoplastic mast cells and the presence of a clonal non-mast cell hematologic neoplasm (e.g., myelodysplastic syndrome, chronic myeloproliferative disorder, acute myeloid leukemia, and lymphoma).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Mastocytosis with an Associated Myeloid Neoplasm","conceptCode":"C9284","definition":"A disorder characterized by systemic infiltration of internal organs by aggregates of clonal mast cells and the presence of a clonal non-mast cell myeloid neoplasm (e.g., myelodysplastic syndrome, myeloproliferative neoplasm, and acute myeloid leukemia).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A98887-3A9A-9A11-E040-BB89AD434E3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A98887-3AB3-9A11-E040-BB89AD434E3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Teratoma - Immature","valueDescription":"Immature Teratoma","ValueMeaning":{"publicId":"2838862","version":"1","preferredName":"Immature Teratoma","longName":"2838862","preferredDefinition":"A teratoma composed of immature, fetal-type tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immature Teratoma","conceptCode":"C4286","definition":"A teratoma characterized by the presence of an extensive component of immature, fetal-type tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A98887-3AC1-9A11-E040-BB89AD434E3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A98887-3ADA-9A11-E040-BB89AD434E3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Teratoma With Malignant Transformation","valueDescription":"Teratoma with Malignant Transformation","ValueMeaning":{"publicId":"2838864","version":"1","preferredName":"Teratoma with Malignant Transformation","longName":"2838864","preferredDefinition":"A teratoma which is characterized by morphologic transformation to malignancy and an aggressive clinical course. The malignant component most often is sarcomatous or carcinomatous.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Teratoma with Somatic-Type Malignancy","conceptCode":"C4289","definition":"A teratoma which is characterized by morphologic transformation to malignancy and an aggressive clinical course. The malignant component most often is sarcomatous or carcinomatous.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A98887-3AE7-9A11-E040-BB89AD434E3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A98887-3B00-9A11-E040-BB89AD434E3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia and Myelodysplastic Syndromes - Other Types","valueDescription":"MDS Other Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2853379","version":"1","preferredName":"MDS Other Acute Myeloid Leukemia","longName":"2853379","preferredDefinition":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003: Not otherwise specified.: A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"657C1DA4-3986-46C8-E040-BB89AD437C19","latestVersionIndicator":"Yes","beginDate":"2009-03-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"657C1DA4-399F-46C8-E040-BB89AD437C19","beginDate":"2009-03-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-03-19","modifiedBy":"ONEDATA","dateModified":"2009-03-19","deletedIndicator":"No"},{"value":"Large Cell Carcinoma - Other Variant","valueDescription":"Other Variation Large Cell Carcinoma","ValueMeaning":{"publicId":"2861337","version":"1","preferredName":"Other Variation Large Cell Carcinoma","longName":"2861337","preferredDefinition":"Not otherwise specified.: Variation; something that deviates from a norm or standard; an instance of change.: These represent the least common histologic subtype of lung cancers comprising approximately 15% of all lung cancers.  The frequency is decreasing with improved classification through refined histopathological analysis of these tumors as poorly differentiated squamous cell carcinomas or adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Variation","conceptCode":"C25713","definition":"An alteration or difference from a norm or standard.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Large Cell Carcinoma","conceptCode":"C3780","definition":"A malignant epithelial neoplasm composed of large, atypical cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AE3308-C6A7-84F3-E040-BB89AD437839","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C6C0-84F3-E040-BB89AD437839","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Invasive Papillary-Mucinous Carcinoma","valueDescription":"Invasive Papillary Mucinous Carcinoma","ValueMeaning":{"publicId":"2861338","version":"1","preferredName":"Invasive Papillary Mucinous Carcinoma","longName":"2861338","preferredDefinition":"Marked by a tendency to spread especially into healthy tissue.: of or relating to or resembling papilla.: containing or resembling mucin.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive","conceptCode":"C14159","definition":"Marked by a tendency to spread, especially into healthy surrounding tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Papillary","conceptCode":"C14166","definition":"Of or relating to or resembling papilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Mucinous","conceptCode":"C14163","definition":"Containing or resembling mucin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AE3308-C6CF-84F3-E040-BB89AD437839","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C6E8-84F3-E040-BB89AD437839","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Invasive Lobular","valueDescription":"Invasive Lobular Carcinoma","ValueMeaning":{"publicId":"2861339","version":"1","preferredName":"Invasive Lobular Carcinoma","longName":"2861339","preferredDefinition":"Marked by a tendency to spread especially into healthy tissue.: Lobular; of or relating to or resembling a lobule.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive","conceptCode":"C14159","definition":"Marked by a tendency to spread, especially into healthy surrounding tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Lobular","conceptCode":"C25557","definition":"Of or relating to or resembling a lobule.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AE3308-C6F6-84F3-E040-BB89AD437839","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C70F-84F3-E040-BB89AD437839","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Invasive Ductal Carcinoma With Paget Disease","valueDescription":"Invasive Ductal Carcinoma, Not Otherwise Specified With Paget's Disease","ValueMeaning":{"publicId":"2861340","version":"1","preferredName":"Invasive Ductal Carcinoma, Not Otherwise Specified With Paget's Disease","longName":"2861340","preferredDefinition":"Invasive ductal carcinoma is the most common type of invasive breast carcinoma (accounting for approximately 70% of breast carcinomas). The gross appearance is usually typical with an irregular stellate outline. Microscopically, randomly arranged epithelial elements are seen. When large sheets of malignant cells are present, necrosis may be seen. With adequate tissue sampling, in situ carcinoma can be demonstrated in association with the infiltrating carcinoma. The in situ component is nearly always ductal but occasionally may be lobular or both. --2002: Used to indicate the presence of something or someone.: A malignant neoplasm composed of large cells with large nuclei, prominent nucleoli, and abundant pale cytoplasm (Paget cells).  Paget's cell neoplasms include Paget's disease of the nipple and extramammary Paget's disease which may affect the vulva, penis, anus, skin and scrotum. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive Breast Carcinoma of No Special Type","conceptCode":"C4194","definition":"A term that refers to a large and heterogeneous group of invasive breast carcinomas that cannot be classified morphologically as any of the special histological types. (WHO 2019)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Paget Disease","conceptCode":"C7073","definition":"A malignant neoplasm composed of large cells with large nuclei, prominent nucleoli, and abundant pale cytoplasm (Paget cells).  Paget cell neoplasms include Paget disease of the nipple and extramammary Paget disease which may affect the vulva, penis, anus, skin and scrotum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AE3308-C71D-84F3-E040-BB89AD437839","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C736-84F3-E040-BB89AD437839","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Extraosseus Plasmacytoma","valueDescription":"Extraosseous Plasmacytoma","ValueMeaning":{"publicId":"2861342","version":"1","preferredName":"Extraosseous Plasmacytoma","longName":"2861342","preferredDefinition":"A plasma cell neoplasm arising at an extraosseous site. There is no involvement of the bone marrow. It most frequently involves the oropharynx, nasopharynx, sinuses, and larynx. Other sites of involvement include the gastrointestinal tract, central nervous system, breast, skin, lymph nodes, and bladder.  A minority of patients have a monoclonal gammopathy. Treatment includes radiation therapy. Progression to plasma cell myeloma occurs in a minority of patients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extraosseous Plasmacytoma","conceptCode":"C4002","definition":"A localized malignant neoplasm arising in an extraosseous site. It is composed of clonal (malignant) plasma cells forming a tumor mass. It most frequently involves the oropharynx, nasopharynx, sinuses, and larynx.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AE3308-C743-84F3-E040-BB89AD437839","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C75C-84F3-E040-BB89AD437839","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Ependymoma - Other","valueDescription":"Other Ependymoma","ValueMeaning":{"publicId":"2861343","version":"1","preferredName":"Other Ependymoma","longName":"2861343","preferredDefinition":"Not otherwise specified.: Ependymoma (WHO grade II) is the most common ependymal neoplasm. It is a slow growing tumor of children and young adults and is usually located intraventricularly.  It often causes clinical symptoms by blocking CSF pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes.(Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ependymoma","conceptCode":"C3017","definition":"A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AE3308-C769-84F3-E040-BB89AD437839","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C782-84F3-E040-BB89AD437839","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Dysembryoplastic Neuroepithelial Tumor","valueDescription":"Dysembryoplastic Neuroepithelial Tumor","ValueMeaning":{"publicId":"2578718","version":"1","preferredName":"Dysembryoplastic Neuroepithelial Tumor","longName":"2578718","preferredDefinition":"Dysembryoplastic Neuroepithelial Tumor (WHO grade I) is a benign glial-neuronal neoplasm. It is usually supratentorial, located, generally, in the cortex and occurs in children and young adults with a long-standing history of partial seizures. A histologic hallmark of this tumor is the 'specific glioneuronal element', characterized by columns, made up of bundles of axons, oriented perpendicularly to the cortical surface. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysembryoplastic Neuroepithelial Tumor","conceptCode":"C9505","definition":"A glial-neuronal neoplasm located in the cortex. It occurs in children and young adults with a long-standing history of partial seizures. A histologic hallmark of this tumor is the 'specific glioneuronal element', characterized by columns, made up of bundles of axons, oriented perpendicularly to the cortical surface. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-008B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C78C-84F3-E040-BB89AD437839","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Desmoplastic Infantile Ganglioglioma or Astrocytoma","valueDescription":"Desmoplastic Infantile Ganglioglioma Or Astrocytoma","ValueMeaning":{"publicId":"2861345","version":"1","preferredName":"Desmoplastic Infantile Ganglioglioma Or Astrocytoma","longName":"2861345","preferredDefinition":"A WHO grade I large cystic tumor that occurs almost exclusively in infants, with a prominent desmoplastic stroma having a neuroepithelial population of neoplastic astrocytes together with a variable neuronal component. They involve the superficial cerebral cortex and leptomeninges, and often attach to the dura. Although clinically they present as large tumors, they generally have a good prognosis following surgical resection. (Adapted from WHO 2000.) - 2004: Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desmoplastic Infantile Ganglioglioma","conceptCode":"C4738","definition":"A WHO grade I large cystic tumor that occurs almost exclusively in infants, with a prominent desmoplastic stroma having a neuroepithelial population of neoplastic astrocytes together with a variable neuronal component. It involves the superficial cerebral cortex and leptomeninges, and often attaches to the dura. Although clinically it presents as a large tumor, it generally has a good prognosis following surgical resection. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AE3308-C79C-84F3-E040-BB89AD437839","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C7B5-84F3-E040-BB89AD437839","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Cutaneous Sezary Syndrome","valueDescription":"Cutaneous Sezary Syndrome","ValueMeaning":{"publicId":"2861346","version":"1","preferredName":"Cutaneous Sezary Syndrome","longName":"2861346","preferredDefinition":"(kyoo-TAY-nee-us) Having to do with the skin.: A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutaneous","conceptCode":"C13316","definition":"Involving the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Sezary Syndrome","conceptCode":"C3366","definition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AE3308-C7C2-84F3-E040-BB89AD437839","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C7DB-84F3-E040-BB89AD437839","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Cutaneous Mycosis Fungoides","valueDescription":"Cutaneous Mycosis Fungoides","ValueMeaning":{"publicId":"2861347","version":"1","preferredName":"Cutaneous Mycosis Fungoides","longName":"2861347","preferredDefinition":"(kyoo-TAY-nee-us) Having to do with the skin.: A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques and it is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutaneous","conceptCode":"C13316","definition":"Involving the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mycosis Fungoides","conceptCode":"C3246","definition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AE3308-C7E8-84F3-E040-BB89AD437839","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C801-84F3-E040-BB89AD437839","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Craniopharyngioma - Other","valueDescription":"Other Craniopharyngioma","ValueMeaning":{"publicId":"2861348","version":"1","preferredName":"Other Craniopharyngioma","longName":"2861348","preferredDefinition":"Not otherwise specified.: Craniopharyngiomas (WHO grade I) are benign, partly cystic, epithelial tumors of the sellar region, presumably derived from Rathke pouch epithelium. They affect mainly children and young adults. There are two clinicopathological forms: Adamantinomatous Craniopharyngioma and Papillary Craniopharyngioma. Recent studies indicate that the age distribution and, to some extent, prognosis are different between these two variants. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Craniopharyngioma","conceptCode":"C2964","definition":"A benign, partly cystic, epithelial tumor of the sellar region, presumably derived from Rathke pouch epithelium. It affects mainly children and young adults. There are two clinicopathological forms: adamantinomatous craniopharyngioma and papillary craniopharyngioma. The most significant factor associated with recurrence is the extent of surgical resection, with lesions greater than 5 cm in diameter carrying a markedly worse prognosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AE3308-C80E-84F3-E040-BB89AD437839","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C827-84F3-E040-BB89AD437839","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Craniopharyngioma - Not Otherwise Characterized","valueDescription":"Not Otherwise Specified Craniopharyngioma","ValueMeaning":{"publicId":"2861349","version":"1","preferredName":"Not Otherwise Specified Craniopharyngioma","longName":"2861349","preferredDefinition":"Not characterized in any other way.: Craniopharyngiomas (WHO grade I) are benign, partly cystic, epithelial tumors of the sellar region, presumably derived from Rathke pouch epithelium. They affect mainly children and young adults. There are two clinicopathological forms: Adamantinomatous Craniopharyngioma and Papillary Craniopharyngioma. Recent studies indicate that the age distribution and, to some extent, prognosis are different between these two variants. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Craniopharyngioma","conceptCode":"C2964","definition":"A benign, partly cystic, epithelial tumor of the sellar region, presumably derived from Rathke pouch epithelium. It affects mainly children and young adults. There are two clinicopathological forms: adamantinomatous craniopharyngioma and papillary craniopharyngioma. The most significant factor associated with recurrence is the extent of surgical resection, with lesions greater than 5 cm in diameter carrying a markedly worse prognosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AE3308-C834-84F3-E040-BB89AD437839","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C84D-84F3-E040-BB89AD437839","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Ependymoma - Not Otherwise Characterized","valueDescription":"Not Otherwise Specified Ependymoma","ValueMeaning":{"publicId":"2861350","version":"1","preferredName":"Not Otherwise Specified Ependymoma","longName":"2861350","preferredDefinition":"Not characterized in any other way.: Ependymoma (WHO grade II) is the most common ependymal neoplasm. It is a slow growing tumor of children and young adults and is usually located intraventricularly.  It often causes clinical symptoms by blocking CSF pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes.(Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ependymoma","conceptCode":"C3017","definition":"A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AE3308-C85A-84F3-E040-BB89AD437839","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AE3308-C873-84F3-E040-BB89AD437839","beginDate":"2009-02-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Small Cell Carcinoma","valueDescription":"Pancreatic Small Cell Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"2838839","version":"1","preferredName":"Pancreatic Small Cell Neuroendocrine Carcinoma","longName":"2838839","preferredDefinition":"An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas.  It is characterized by the presence of malignant small cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Small Cell Neuroendocrine Carcinoma","conceptCode":"C95583","definition":"An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. It is characterized by the presence of malignant small cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A9743A-23D9-8C94-E040-BB89AD4308C2","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"HARTLEYG","dateModified":"2017-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A9743A-23F2-8C94-E040-BB89AD4308C2","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Combined Small Cell Carcinoma","valueDescription":"Combined Small Cell Carcinoma","ValueMeaning":{"publicId":"2861306","version":"1","preferredName":"Combined Small Cell Carcinoma","longName":"2861306","preferredDefinition":"Made or joined or united into one or involving the joint activity of two or more.: A neuroendocrine carcinoma composed of small malignant cells which are often said to resemble \"oat cells\" under the microscope.  Small cell carcinoma most often affects the lungs.  Clinically, this is often a rapidly growing cancer that spreads to distant sites early.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Combined","conceptCode":"C25454","definition":"Made or joined or united into one or involving the joint activity of two or more.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Small Cell Neuroendocrine Carcinoma","conceptCode":"C3915","definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation. It is composed of malignant small cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AD9A2F-12AB-E58B-E040-BB89AD437C2B","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AD9A2F-12C4-E58B-E040-BB89AD437C2B","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Chronic Eosinophilic Leukemia Or Hypereosinophilic Syndrome","valueDescription":"Chronic Eosinophilic Leukemia Or Hypereosinophilic Syndrome","ValueMeaning":{"publicId":"2861308","version":"1","preferredName":"Chronic Eosinophilic Leukemia Or Hypereosinophilic Syndrome","longName":"2861308","preferredDefinition":"A rare chronic myeloproliferative disorder characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001) -- 2003: Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction.  This term has often been applied to cases of chronic eosinophilic leukemia.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","conceptCode":"C4563","definition":"A rare myeloproliferative neoplasm characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Idiopathic Hypereosinophilic Syndrome","conceptCode":"C27038","definition":"A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction.  This term has often been applied to cases of chronic eosinophilic leukemia.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AD9A2F-12D3-E58B-E040-BB89AD437C2B","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AD9A2F-12EC-E58B-E040-BB89AD437C2B","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Chromophobe Renal Carcinoma","valueDescription":"Chromophobe Renal Cell Carcinoma","ValueMeaning":{"publicId":"2581665","version":"1","preferredName":"Chromophobe Renal Cell Carcinoma","longName":"2581665","preferredDefinition":"A type of carcinoma that comprises a minority of renal cell carcinomas.  It is characterized by loss of chromosomes 1 and Y.  Based on the cytoplasmic characteristics of the neoplastic cells, this type of carcinoma is classified as classic (typical) or eosinophilic.  It has a much better prognosis than other renal cell carcinomas.  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chromophobe Renal Cell Carcinoma","conceptCode":"C4146","definition":"A type of carcinoma that comprises a minority of renal cell carcinomas.  It is characterized by loss of chromosomes 1 and Y.  Based on the cytoplasmic characteristics of the neoplastic cells, this type of carcinoma is classified as classic (typical), eosinophilic, or oncocytic.  It has a much better prognosis than other renal cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C0E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-09","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-09","modifiedBy":"ONEDATA","dateModified":"2006-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AD9A2F-1300-E58B-E040-BB89AD437C2B","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Carcinoma With Metaplasia - Mixed Type","valueDescription":"Mixed Metaplasia Carcinoma","ValueMeaning":{"publicId":"2861311","version":"1","preferredName":"Mixed Metaplasia Carcinoma","longName":"2861311","preferredDefinition":"Involving or composed of different kinds.: Transformation of a mature, normal cell or groups of mature cells to other forms of mature cells.  The capacity for malignant transformation of metaplastic cells is a subject of controversy.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed","conceptCode":"C25259","definition":"Involving or composed of different kinds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Metaplasia","conceptCode":"C3236","definition":"Transformation of a mature, normal cell or groups of mature cells to other forms of mature cells.  The capacity for malignant transformation of metaplastic cells is a subject of controversy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AD9A2F-1338-E58B-E040-BB89AD437C2B","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AD9A2F-1351-E58B-E040-BB89AD437C2B","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Carcinoma - type cannot be determined","valueDescription":"Indeterminate Carcinoma","ValueMeaning":{"publicId":"2861312","version":"1","preferredName":"Indeterminate Carcinoma","longName":"2861312","preferredDefinition":"Cannot distinguish between two or more possible values in the current context.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate","conceptCode":"C48658","definition":"Cannot distinguish between two or more possible values in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AD9A2F-135E-E58B-E040-BB89AD437C2B","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AD9A2F-1377-E58B-E040-BB89AD437C2B","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Adenoid Cystic","valueDescription":"Adenoid Cystic Carcinoma","ValueMeaning":{"publicId":"2836817","version":"1","preferredName":"Adenoid Cystic Carcinoma","longName":"2836817","preferredDefinition":"A malignant tumor arising from the epithelial cells, also known as cylindroma.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoid Cystic Carcinoma","conceptCode":"C2970","definition":"A malignant tumor arising from the epithelial cells.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"624748BE-AA6A-D571-E040-BB89AD4336CB","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67ACCB6B-ECB6-FC03-E040-BB89AD4318C7","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Adenocarcinoma - NOS","valueDescription":"Not Otherwise Specified Adenocarcinoma","ValueMeaning":{"publicId":"2861284","version":"1","preferredName":"Not Otherwise Specified Adenocarcinoma","longName":"2861284","preferredDefinition":"Not characterized in any other way.: carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67ACCB6B-ECC3-FC03-E040-BB89AD4318C7","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67ACCB6B-ECDC-FC03-E040-BB89AD4318C7","beginDate":"2009-02-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Atypical Carcinoid Tumor","valueDescription":"Atypical Carcinoid Tumor","ValueMeaning":{"publicId":"2861147","version":"1","preferredName":"Atypical Carcinoid Tumor","longName":"2861147v1.00","preferredDefinition":"A carcinoid tumor characterized by a high mitotic rate, often associated with the presence of necrosis and nuclear pleomorphism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroendocrine Tumor G2","conceptCode":"C72074","definition":"A well-differentiated, intermediate-grade epithelial neoplasm with neuroendocrine differentiation. It usually arises from the digestive system, lung, and head and neck.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"679989A6-3C87-41F6-E040-BB89AD43246A","latestVersionIndicator":"Yes","beginDate":"2009-04-15","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-04-15","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"679989A6-3C9F-41F6-E040-BB89AD43246A","beginDate":"2009-04-15","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-04-15","modifiedBy":"ONEDATA","dateModified":"2009-04-15","deletedIndicator":"No"},{"value":"Astrocytoma - Other","valueDescription":"Other Astrocytoma","ValueMeaning":{"publicId":"2861145","version":"1","preferredName":"Other Astrocytoma","longName":"2861145","preferredDefinition":"Not otherwise specified.: A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"679989A6-3C61-41F6-E040-BB89AD43246A","latestVersionIndicator":"Yes","beginDate":"2009-04-15","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"679989A6-3CCB-41F6-E040-BB89AD43246A","beginDate":"2009-04-15","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-04-15","modifiedBy":"ONEDATA","dateModified":"2009-04-15","deletedIndicator":"No"},{"value":"Burkitt Lymphoma Or Leukemia","valueDescription":"Burkitt's Lymphoma Or Burkitt's Leukemia","ValueMeaning":{"publicId":"2861313","version":"1","preferredName":"Burkitt's Lymphoma Or Burkitt's Leukemia","longName":"2861313","preferredDefinition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt's lymphoma, Burkitt's lymphoma with plasmacytoid differentiation, and atypical Burkitt's/Burkitt's-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001) -- 2003: Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: The leukemic counterpart of Burkitt's lymphoma.  The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood.  This is an aggressive leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt Lymphoma","conceptCode":"C2912","definition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Burkitt Leukemia","conceptCode":"C7400","definition":"The leukemic counterpart of Burkitt's lymphoma. The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood. This is an aggressive leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AD9A2F-1385-E58B-E040-BB89AD437C2B","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AD9A2F-139E-E58B-E040-BB89AD437C2B","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Bronchioloalveolar Carcinoma - Variant","valueDescription":"Variation Bronchioloalveolar Carcinoma","ValueMeaning":{"publicId":"2861314","version":"1","preferredName":"Variation Bronchioloalveolar Carcinoma","longName":"2861314","preferredDefinition":"Variation; something that deviates from a norm or standard; an instance of change.: A well or moderately differentiated morphologic variant of lung adenocarcinoma characterized by tumor growth along the alveolar structures without stromal, vascular, or pleural invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Variation","conceptCode":"C25713","definition":"An alteration or difference from a norm or standard.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Minimally Invasive Lung Adenocarcinoma","conceptCode":"C2923","definition":"A solitary adenocarcinoma arising from the lung and measuring 3 cm or less in size. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AD9A2F-13AB-E58B-E040-BB89AD437C2B","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AD9A2F-13C4-E58B-E040-BB89AD437C2B","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Basoloid Carcinoma","valueDescription":"Basaloid Carcinoma","ValueMeaning":{"publicId":"2861316","version":"1","preferredName":"Basaloid Carcinoma","longName":"2861316","preferredDefinition":"A malignant epithelial neoplasm characterized by the presence of neoplastic cells with hyperchromatic nuclei, small amount of cytoplasm, and peripheral nuclear palisading.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Basaloid Carcinoma","conceptCode":"C4121","definition":"A malignant epithelial neoplasm characterized by the presence of neoplastic cells with hyperchromatic nuclei, small amount of cytoplasm, and peripheral nuclear palisading.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AD9A2F-13D1-E58B-E040-BB89AD437C2B","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AD9A2F-13EA-E58B-E040-BB89AD437C2B","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Atypical Tertoid Or Rhabdoid Tumor","valueDescription":"Atypical Teratoid/Rhabdoid Tumor","ValueMeaning":{"publicId":"2578728","version":"1","preferredName":"Atypical Teratoid/Rhabdoid Tumor","longName":"2578728","preferredDefinition":"Atypical teratoid/rhabdoid tumor (WHO grade IV) is a malignant embryonal CNS tumor which occurs in children and is composed of rhabdoid cells, with or without fields resembling a classical primitive neuroectodermal tumor (PNET), epithelial tissue and neoplastic mesenchyme. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Teratoid/Rhabdoid Tumor","conceptCode":"C6906","definition":"An aggressive malignant embryonal neoplasm arising from the central nervous system. It is composed of cells with a large eccentric nucleus, prominent nucleolus, and abundant cytoplasm. Mutations of the SMARCB1 gene or very rarely SMARCA4 (BRG1) gene are present. The vast majority of cases occur in childhood. Symptoms include lethargy, vomiting, cranial nerve palsy, headache, and hemiplegia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0095-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"ONEDATA","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AD9A2F-13FE-E58B-E040-BB89AD437C2B","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Astrocytoma - Not Otherwise Characterized","valueDescription":"Not Otherwise Specified Astrocytoma","ValueMeaning":{"publicId":"2861317","version":"1","preferredName":"Not Otherwise Specified Astrocytoma","longName":"2861317","preferredDefinition":"Not characterized in any other way.: A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67AD9A2F-140C-E58B-E040-BB89AD437C2B","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67AD9A2F-1425-E58B-E040-BB89AD437C2B","beginDate":"2009-02-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Squamous Cell Carcinoma - Variant","valueDescription":"Variation Squamous Cell Carcinoma","ValueMeaning":{"publicId":"2861474","version":"1","preferredName":"Variation Squamous Cell Carcinoma","longName":"2861474","preferredDefinition":"Variation; something that deviates from a norm or standard; an instance of change.: A carcinoma derived from stratified squamous epithelium. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Variation","conceptCode":"C25713","definition":"An alteration or difference from a norm or standard.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Squamous Cell Carcinoma","conceptCode":"C2929","definition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C4B101-BA8F-9EDF-E040-BB89AD432E9F","latestVersionIndicator":"Yes","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C4B101-BAA8-9EDF-E040-BB89AD432E9F","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Schwannoma - Other","valueDescription":"Other Schwannoma","ValueMeaning":{"publicId":"2861475","version":"1","preferredName":"Other Schwannoma","longName":"2861475","preferredDefinition":"Not otherwise specified.: A tumor of the peripheral nervous system that arises in the nerve sheath (protective covering).  It is almost always benign, but rare malignant schwannomas have been reported.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Schwannoma","conceptCode":"C3269","definition":"A benign, usually encapsulated slow growing tumor composed of Schwann cells.  It affects peripheral and cranial nerves.  It recurs infrequently and only rare cases associated with malignant transformation have been reported.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C4B101-BAB5-9EDF-E040-BB89AD432E9F","latestVersionIndicator":"Yes","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C4B101-BACE-9EDF-E040-BB89AD432E9F","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Sarcomatoid Carcinoma Arising in Renal cell Carcinoma","valueDescription":"Sarcomatoid Carcinoma Renal Cell Carcinoma","ValueMeaning":{"publicId":"2861476","version":"1","preferredName":"Sarcomatoid Carcinoma Renal Cell Carcinoma","longName":"2861476","preferredDefinition":"Cancer that arises in cells that appear spindle-shaped when viewed under a microscope. These cancers can occur in various places in the body, including the skin, lungs, kidney, breast, gastrointestinal tract, bone, and muscle.: Cancer that develops in the lining of the renal tubules, which filter the blood and produce urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcomatoid Carcinoma","conceptCode":"C27004","definition":"A malignant epithelial neoplasm characterized by the presence of spindle cells and anaplastic morphologic features.  Giant cells and a sarcomatous component may also be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Renal Cell Carcinoma","conceptCode":"C9385","definition":"A carcinoma arising from the renal parenchyma.  There is a strong correlation between cigarette smoking and the development of renal cell carcinoma.  The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass.  A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes.  Radical nephrectomy is the standard intervention procedure.  Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C4B101-BADB-9EDF-E040-BB89AD432E9F","latestVersionIndicator":"Yes","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C4B101-BAF4-9EDF-E040-BB89AD432E9F","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Papillary Renal Carcinoma","valueDescription":"Papillary Renal Cell Carcinoma","ValueMeaning":{"publicId":"2581626","version":"1","preferredName":"Papillary Renal Cell Carcinoma","longName":"2581626","preferredDefinition":"Also known as chromophil carcinoma, it represents a minority of renal cell carcinomas.  It can be hereditary or sporadic.  The sporadic papillary renal cell carcinoma is characterized by trisomy of chromosomes 7, 16, and 17, and loss of chromosome Y.  The peak incidence is in the sixth and seven decades.  It is classified as type 1 or 2, based on the cytoplasmic volume and the thickness of the lining neoplastic cells. The prognosis is more favorable than for conventional (clear cell) renal cell carcinoma. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Renal Cell Carcinoma","conceptCode":"C6975","definition":"Also known as chromophil carcinoma, it represents a minority of renal cell carcinomas.  It can be hereditary or sporadic.  The sporadic papillary renal cell carcinoma is characterized by trisomy of chromosomes 7, 16, and 17, and loss of chromosome Y.  The peak incidence is in the sixth and seven decades.  It is classified as type 1 or 2, based on the cytoplasmic volume and the thickness of the lining neoplastic cells. The prognosis is more favorable than for conventional (clear cell) renal cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0BE7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-07","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-07","modifiedBy":"ONEDATA","dateModified":"2006-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C4B101-BB2E-9EDF-E040-BB89AD432E9F","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Other Tumor Of Salivary Gland Type","valueDescription":"Other Neoplasm Salivary Gland","ValueMeaning":{"publicId":"2861478","version":"1","preferredName":"Other Neoplasm Salivary Gland","longName":"2861478","preferredDefinition":"Not otherwise specified.: (NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.: An exocrine gland that secretes saliva.  Salivary glands are mostly located in and around the oral cavity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Salivary Gland","conceptCode":"C12426","definition":"An exocrine gland that secretes saliva. Salivary glands are mostly located in and around the oral cavity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C4B101-BB3D-9EDF-E040-BB89AD432E9F","latestVersionIndicator":"Yes","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C4B101-BB56-9EDF-E040-BB89AD432E9F","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Noninvasive Carcinoma - NOS","valueDescription":"Not Otherwise Specified Non-invasive Lesion Carcinoma","ValueMeaning":{"publicId":"2861479","version":"1","preferredName":"Not Otherwise Specified Non-invasive Lesion Carcinoma","longName":"2861479","preferredDefinition":"Not characterized in any other way.: A neoplastic process that is confined to the site of origin without morphologic evidence of cellular infiltration of the surrounding tissue.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Non-Invasive Lesion","conceptCode":"C36027","definition":"A neoplastic process that is confined to the site of origin without morphologic evidence of cellular infiltration of the surrounding tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C4B101-BB64-9EDF-E040-BB89AD432E9F","latestVersionIndicator":"Yes","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C4B101-BB7D-9EDF-E040-BB89AD432E9F","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Nodal Peripheral T-Cell Lymphoma - Unspecified","valueDescription":"Nodal Unspecified Peripheral T-Cell Lymphoma","ValueMeaning":{"publicId":"2861480","version":"1","preferredName":"Nodal Unspecified Peripheral T-Cell Lymphoma","longName":"2861480","preferredDefinition":"Nodal; of or pertaining to a node, any bulge or swelling of an anatomical structure or part.: Aggressive nodal or extranodal mature (peripheral) T-cell lymphomas that do not belong to the better defined entities of the remainder of mature T-cell lymphomas.  This category includes the lymphoepithelioid cell variant of mature T-cell lymphoma (Lennert's lymphoma) and the T-zone variant of mature T-cell lymphoma.--2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodal","conceptCode":"C25323","definition":"Of or pertaining to a node, any bulge or swelling of an anatomical structure or part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C4340","definition":"A group of peripheral T-cell lymphomas that do not meet the criteria for any other category of specifically defined entities of peripheral T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C4B101-BB8A-9EDF-E040-BB89AD432E9F","latestVersionIndicator":"Yes","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C4B101-BBA3-9EDF-E040-BB89AD432E9F","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Nodal Angioimmunoblastic T-Cell Lymphoma","valueDescription":"Nodal Angioimmunoblastic T-Cell Lymphoma","ValueMeaning":{"publicId":"2861481","version":"1","preferredName":"Nodal Angioimmunoblastic T-Cell Lymphoma","longName":"2861481","preferredDefinition":"Nodal; of or pertaining to a node, any bulge or swelling of an anatomical structure or part.: A mature T-cell non-Hodgkin's lymphoma, characterized by systemic disease and a polymorphous infiltrate involving lymph nodes.  It occurs in the middle aged and elderly, with an equal incidence in males and females.  The clinical course is typically aggressive.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodal","conceptCode":"C25323","definition":"Of or pertaining to a node, any bulge or swelling of an anatomical structure or part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type","conceptCode":"C7528","definition":"An aggressive follicular helper T-cell lymphoma affecting lymph nodes and other sites. It is characterized by a polymorphous infiltrate and prominent proliferation of high endothelial venules and follicular dendritic cells. It is associated with EBV infection and affects mainly older adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C4B101-BBB0-9EDF-E040-BB89AD432E9F","latestVersionIndicator":"Yes","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C4B101-BBC9-9EDF-E040-BB89AD432E9F","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Nodal Anaplastic Large Cell Lymphoma","valueDescription":"Nodal Anaplastic Large Cell Lymphoma","ValueMeaning":{"publicId":"2861482","version":"1","preferredName":"Nodal Anaplastic Large Cell Lymphoma","longName":"2861482","preferredDefinition":"Nodal; of or pertaining to a node, any bulge or swelling of an anatomical structure or part.: A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells.  Majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein.  The most frequently seen genetic alteration is a t(2;5) translocation.  Majority of patients present with advanced disease.  The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodal","conceptCode":"C25323","definition":"Of or pertaining to a node, any bulge or swelling of an anatomical structure or part.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anaplastic Large Cell Lymphoma","conceptCode":"C3720","definition":"A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C4B101-BBD6-9EDF-E040-BB89AD432E9F","latestVersionIndicator":"Yes","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C4B101-BBEF-9EDF-E040-BB89AD432E9F","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Apocrine","valueDescription":"Apocrine Cell","ValueMeaning":{"publicId":"2861843","version":"1","preferredName":"Apocrine Cell","longName":"2861843","preferredDefinition":"A glandular secreting cell in which the apical portion of the secreting cell is cast off along with the secretory products that have accumulated therein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apocrine Cell","conceptCode":"C43374","definition":"A glandular secreting cell in which the apical portion of the secreting cell is cast off along with the secretory products that have accumulated therein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6815D539-E837-D84D-E040-BB89AD43176C","latestVersionIndicator":"Yes","beginDate":"2009-04-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-21","modifiedBy":"ONEDATA","dateModified":"2009-04-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6815D539-E850-D84D-E040-BB89AD43176C","beginDate":"2009-03-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-21","modifiedBy":"ONEDATA","dateModified":"2009-04-21","deletedIndicator":"No"},{"value":"Histiocytic Sarcoma","valueDescription":"Histiocytic Sarcoma","ValueMeaning":{"publicId":"2864914","version":"1","preferredName":"Histiocytic Sarcoma","longName":"2864914","preferredDefinition":"An aggressive malignant neoplasm with a poor response to therapy, usually presenting as stage III/IV disease.  It is characterized by the presence of neoplastic cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histiocytic Sarcoma","conceptCode":"C27349","definition":"An aggressive malignant neoplasm with a poor response to therapy, usually presenting as stage III/IV disease. It is characterized by the presence of neoplastic cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"689FD4E4-A1CC-9A6F-E040-BB89AD432DE8","latestVersionIndicator":"Yes","beginDate":"2009-04-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-28","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"689FD4E4-A1E4-9A6F-E040-BB89AD432DE8","beginDate":"2009-02-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-28","modifiedBy":"ONEDATA","dateModified":"2009-04-28","deletedIndicator":"No"},{"value":"Prostatic Duct Adenocarcinoma","valueDescription":"Prostatic Duct Adenocarcinoma","ValueMeaning":{"publicId":"2861844","version":"1","preferredName":"Prostatic Duct Adenocarcinoma","longName":"2861844","preferredDefinition":"A small canal that receives prostatic secretions from the glandular tubules and discharges it through the prostatic portion of the urethra.: carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostatic Duct","conceptCode":"C13102","definition":"A small canal that receives prostatic secretions from the glandular tubules and discharges it through the prostatic portion of the urethra.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6815D539-E86E-D84D-E040-BB89AD43176C","latestVersionIndicator":"Yes","beginDate":"2009-04-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6815D539-E886-D84D-E040-BB89AD43176C","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-21","modifiedBy":"ONEDATA","dateModified":"2009-04-21","deletedIndicator":"No"},{"value":"Carcinoma With Pleomorphic/Sarcomatoid/Sarcomatous Elements","valueDescription":"Pleomorphic Sarcomatoid Carcinoma Sarcomatous Component Present Carcinoma","ValueMeaning":{"publicId":"2864913","version":"1","preferredName":"Pleomorphic Sarcomatoid Carcinoma Sarcomatous Component Present Carcinoma","longName":"2864913","preferredDefinition":"Occurring in various distinct forms.  In terms of cells, having variation in the size and shape of cells or their nuclei.: Cancer that arises in cells that appear spindle-shaped when viewed under a microscope. These cancers can occur in various places in the body, including the skin, lungs, kidney, breast, gastrointestinal tract, bone, and muscle.: A histopathologic finding characterized by the presence of malignant cells of connective tissue origin in tumor sample.  Examples of connective tissue cells that can undergo malignanat transformation include smooth and skeletal muscel cells, adipose tissue cells, osteocytes, and chondrocytes.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleomorphic","conceptCode":"C28109","definition":"Occurring in various distinct forms.  In terms of cells, having variation in the size and shape of cells or their nuclei.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Sarcomatoid Carcinoma","conceptCode":"C27004","definition":"A malignant epithelial neoplasm characterized by the presence of spindle cells and anaplastic morphologic features.  Giant cells and a sarcomatous component may also be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Sarcomatous Component Present","conceptCode":"C54727","definition":"A histopathologic finding characterized by the presence of malignant cells of connective tissue origin in a tumor sample.  Examples of connective tissue cells that can undergo malignant transformation include smooth and skeletal muscle cells, adipose tissue cells, osteocytes, and chondrocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"689FD4E4-A1A9-9A6F-E040-BB89AD432DE8","latestVersionIndicator":"Yes","beginDate":"2009-04-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"689FD4E4-A1C1-9A6F-E040-BB89AD432DE8","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-28","modifiedBy":"ONEDATA","dateModified":"2009-04-28","deletedIndicator":"No"},{"value":"Undifferentiated Anaplastic Carcinoma","valueDescription":"Undifferentiated Carcinoma Cell","ValueMeaning":{"publicId":"2864927","version":"1","preferredName":"Undifferentiated Carcinoma Cell","longName":"2864927","preferredDefinition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.: The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated Carcinoma","conceptCode":"C3692","definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cell","conceptCode":"C12508","definition":"The smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"689FFA06-6EC8-8267-E040-BB89AD434595","latestVersionIndicator":"Yes","beginDate":"2009-04-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"689FFA06-6EE1-8267-E040-BB89AD434595","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-28","modifiedBy":"ONEDATA","dateModified":"2009-04-28","deletedIndicator":"No"},{"value":"Acute Leukemia of Ambiguous Lineage","valueDescription":"Acute Leukemia of Ambiguous Lineage","ValueMeaning":{"publicId":"2835647","version":"1","preferredName":"Acute Leukemia of Ambiguous Lineage","longName":"2835647","preferredDefinition":"An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells.  The prognosis is usually unfavorable.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia of Ambiguous Lineage","conceptCode":"C7464","definition":"An acute leukemia in which the blasts lack sufficient evidence to classify as myeloid or lymphoid or they have morphologic and/or immunophenotypic characteristics of both myeloid and lymphoid cells. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-667C-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","changeDescription":null,"administrativeNotes":"2023.3.13 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-6695-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acral Lentiginous Melanoma","valueDescription":"Acral Lentiginous Malignant Melanoma","ValueMeaning":{"publicId":"2835648","version":"1","preferredName":"Acral Lentiginous Malignant Melanoma","longName":"2835648","preferredDefinition":"A form of melanoma occurring most often on the plantar, palmar, subungual, and periungual skin. It presents as a pigmented macular lesion with irregular borders. Morphologically, it consists of atypical spindled and dendritic melanocytes. The epidermis is often hyperplastic and there is pagetoid infiltration of the epidermis by anaplastic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acral Lentiginous Melanoma","conceptCode":"C4022","definition":"A form of melanoma occurring most often on the plantar, palmar, subungual, and periungual skin.  It presents as a pigmented macular lesion with irregular borders.  Morphologically, it consists of atypical spindled and dendritic melanocytes.  The epidermis is often hyperplastic and there is pagetoid infiltration of the epidermis by anaplastic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-669F-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-66B8-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acinar Cell Cystadenocarcinoma","valueDescription":"Pancreatic Acinar Cell Cystadenocarcinoma","ValueMeaning":{"publicId":"2581795","version":"1","preferredName":"Pancreatic Acinar Cell Cystadenocarcinoma","longName":"2581795","preferredDefinition":"A cystic adenocarcinoma characterized by the presence of relatively uniform neoplastic cells which produce pancreatic enzymes and are arranged in acinar patterns. Signs and symptoms include abdominal pain, weight loss, nausea, and diarrhea. It usually has an aggressive clinical course.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Acinar Cell Cystadenocarcinoma","conceptCode":"C5727","definition":"A cystic adenocarcinoma characterized by the presence of relatively uniform neoplastic cells which produce pancreatic enzymes and are arranged in acinar patterns. Signs and symptoms include abdominal pain, weight loss, nausea, and diarrhea. It usually has an aggressive clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C90-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-10","modifiedBy":"CURTIST","dateModified":"2007-12-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-66CC-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acinar Cell Carcinoma","valueDescription":"Acinar Cell Carcinoma","ValueMeaning":{"publicId":"2835649","version":"1","preferredName":"Acinar Cell Carcinoma","longName":"2835649","preferredDefinition":"A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acinar Cell Carcinoma","conceptCode":"C3768","definition":"A malignant glandular epithelial neoplasm consisting of secretory cells forming acinar patterns. Representative examples include the acinar cell carcinoma of the pancreas and the acinar adenocarcinoma of the prostate gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-66D7-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-66F0-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Leukemia of Ambiguous Lineage - Undifferentiated Acute Leukemia","valueDescription":"acute undifferentiated leukemia","ValueMeaning":{"publicId":"2579702","version":"1","preferredName":"acute undifferentiated leukemia","longName":"2579702","preferredDefinition":"An acute leukemia of ambiguous lineage in which the blasts lack sufficient evidence to classify as myeloid or lymphoid.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Undifferentiated Leukemia","conceptCode":"C9299","definition":"An acute leukemia of ambiguous lineage in which the blasts lack sufficient evidence to classify as myeloid or lymphoid.  (WHO, 2001) -- 2003","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0463-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-14","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-14","modifiedBy":"CAMPBELB","dateModified":"2007-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-6705-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Leukemia of Ambiguous Lineage - Biphenotypic Acute Leukemia","valueDescription":"Acute Biphenotypic Leukemia","ValueMeaning":{"publicId":"2672738","version":"1","preferredName":"Acute Biphenotypic Leukemia","longName":"2672738","preferredDefinition":"An acute leukemia of ambiguous lineage characterized by blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Biphenotypic Leukemia","conceptCode":"C4673","definition":"An acute leukemia of ambiguous lineage characterized by blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37BE0FBC-A530-35B4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-671A-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Leukemia of Ambiguous Lineage - Bilineal Acute Leukemia","valueDescription":"Acute Bilineal Leukemia","ValueMeaning":{"publicId":"2835651","version":"1","preferredName":"Acute Bilineal Leukemia","longName":"2835651","preferredDefinition":"An acute leukemia of ambiguous lineage in which there is a dual population of blasts with each population expressing markers of a distinct lineage (myeloid and lymphoid or B-and T-lymphocyte).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Bilineal Leukemia","conceptCode":"C6923","definition":"An acute leukemia of ambiguous lineage in which there is a dual population of blasts with each population expressing markers of a distinct lineage (myeloid and lymphoid or B-and T-lymphocyte).  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-6728-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-6741-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia - Acute Erythroid Leukemia","valueDescription":"Acute Erythroid Leukemia","ValueMeaning":{"publicId":"2836778","version":"1","preferredName":"Acute Erythroid Leukemia","longName":"2836778","preferredDefinition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Erythroid Leukemia","conceptCode":"C8923","definition":"An acute myeloid leukemia characterized by a predominant immature erythroid population.  There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-675B-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-6774-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia - Acute Basophilic Leukemia","valueDescription":"Acute Basophilic Leukemia","ValueMeaning":{"publicId":"2836779","version":"1","preferredName":"Acute Basophilic Leukemia","longName":"2836779","preferredDefinition":"A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Basophilic Leukemia","conceptCode":"C3164","definition":"A rare acute myeloid leukemia in which the immature cells differentiate towards basophils.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-677E-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"COOPERM","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-6797-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia - Acute Monoblastic and Monocytic Leukemia","valueDescription":"Acute Monoblastic Leukemia and Acute Monocytic Leukemia","ValueMeaning":{"publicId":"2672724","version":"1","preferredName":"Acute Monoblastic Leukemia and Acute Monocytic Leukemia","longName":"2672724","preferredDefinition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage.  Bleeding disorders are common presenting features.  It usually follows an aggressive clinical course.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Monoblastic and Monocytic Leukemia","conceptCode":"C7318","definition":"Acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage, including monoblasts, promonocytes, and monocytes. Bleeding disorders are common presenting features.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37BD0487-E0F4-6FAB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-67C3-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia - Acute Megakaryoblastic Leukemia","valueDescription":"Acute Megakaryoblastic Leukemia","ValueMeaning":{"publicId":"2836783","version":"1","preferredName":"Acute Megakaryoblastic Leukemia","longName":"2836783","preferredDefinition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Megakaryoblastic Leukemia","conceptCode":"C3170","definition":"An acute myeloid leukemia in which at least 50% of the blasts are of megakaryocytic lineage. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-67CE-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-67E7-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia - Acute Panmyelosis With Myelofibrosis","valueDescription":"Acute Panmyelosis with Myelofibrosis","ValueMeaning":{"publicId":"2836784","version":"1","preferredName":"Acute Panmyelosis with Myelofibrosis","longName":"2836784","preferredDefinition":"An acute myeloid leukemia characterized by bone marrow fibrosis without preexisting primary myelofibrosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Panmyelosis with Myelofibrosis","conceptCode":"C4344","definition":"An acute myeloid leukemia characterized by bone marrow fibrosis without preexisting primary myelofibrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-67F2-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-680B-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia - Acute Myelomonocytic Leukemia","valueDescription":"Acute Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2836785","version":"1","preferredName":"Acute Myelomonocytic Leukemia","longName":"2836785","preferredDefinition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myelomonocytic Leukemia","conceptCode":"C7463","definition":"An acute leukemia characterized by the proliferation of both neutrophil and monocyte precursors.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62459E81-6815-8F6B-E040-BB89AD43368B","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62459E81-682E-8F6B-E040-BB89AD43368B","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Astrocytoma - Diffuse","valueDescription":"Diffuse astrocytoma","ValueMeaning":{"publicId":"2578704","version":"1","preferredName":"Diffuse astrocytoma","longName":"2578704","preferredDefinition":"A low-grade (WHO grade II) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Astrocytoma","conceptCode":"C7173","definition":"A low-grade (WHO grade 2) astrocytic neoplasm. It is characterized by diffuse infiltration of neighboring central nervous system structures. These lesions typically affect young adults and have a tendency for progression to anaplastic astrocytoma and glioblastoma. Based on the IDH genes mutation status, diffuse astrocytomas are classified as IDH-mutant, IDH-wildtype, and not otherwise specified.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-007D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-10","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2004-03-10","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"628169CF-833D-F4D3-E040-BB89AD433D78","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Astrocytoma - Anaplastic","valueDescription":"Anaplastic astrocytoma","ValueMeaning":{"publicId":"2572930","version":"1","preferredName":"Anaplastic astrocytoma","longName":"2572930","preferredDefinition":"A diffusely infiltrating, WHO grade III astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Astrocytoma","conceptCode":"C9477","definition":"A diffusely infiltrating, WHO grade 3 astrocytoma with focal or dispersed anaplasia, and a marked proliferative potential. It may arise from a low-grade astrocytoma, but it can also be diagnosed at first biopsy, without indication of a less malignant precursor lesion. It has an intrinsic tendency for malignant progression to glioblastoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9EF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"628169CF-8352-F4D3-E040-BB89AD433D78","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Germinoma","valueDescription":"Germinoma","ValueMeaning":{"publicId":"2578733","version":"1","preferredName":"Germinoma","longName":"2578733","preferredDefinition":"The most common type of germ cell tumor affecting the central nervous system.  It is composed of uniform cells with large vesicular nuclei, prominent nucleoli and clear cytoplasm.  Lymphocytic or lymphoplasmacytic infiltrates are usually seen admixed with the tumor cells.  Less frequently giant syncytiotrophoblastic cells are also present.  Germinomas are usually radiosensitive and they have a favorable prognosis.  - 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Germinoma","conceptCode":"C3753","definition":"A malignant germ cell tumor arising in the central nervous system. It is characterized by the presence of primitive, large malignant germ cells and lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-009A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-56E8-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Ganglioglioma","valueDescription":"Ganglioglioma","ValueMeaning":{"publicId":"2578714","version":"1","preferredName":"Ganglioglioma","longName":"2578714","preferredDefinition":"Ganglioglioma (WHO grade I or II) and Gangliocytoma (WHO grade I) are well differentiated, slow growing neuroepithelial neoplasms composed of neoplastic, mature ganglion cells either alone (gangliocytoma), or in combination with neoplastic glial cells (ganglioglioma). Some Gangliogliomas show anaplastic features in their glial component and are considered to be WHO grade III (see 'Anaplastic Ganglioglioma). There are rare cases of newly diagnosed Gangliogliomas with grade IV (Glioblastoma) changes in the glial component. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganglioglioma","conceptCode":"C3788","definition":"A well differentiated, slow growing neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and neoplastic glial cells. Some gangliogliomas show anaplastic features in their glial component and are considered to be WHO grade III. Rare cases of newly diagnosed gangliogliomas with grade IV (glioblastoma) changes in the glial component have also been reported. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0087-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-56F3-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Gangliocytoma","valueDescription":"Gangliocytoma","ValueMeaning":{"publicId":"2578713","version":"1","preferredName":"Gangliocytoma","longName":"2578713","preferredDefinition":"Gangliocytoma (WHO grade I) and Ganglioglioma (WHO grade I or II) are well differentiated, slow growing neuroepithelial neoplasms composed of neoplastic, mature ganglion cells either alone (gangliocytoma), or in combination with neoplastic glial cells (ganglioglioma). (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gangliocytoma","conceptCode":"C6934","definition":"A well differentiated, slow growing neuroepithelial neoplasm composed of neoplastic, mature ganglion cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0086-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-56FE-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Invasive Ductal Carcinoma (NOS)","valueDescription":"Invasive Ductal Carcinoma, Not Otherwise Specified","ValueMeaning":{"publicId":"2581223","version":"1","preferredName":"Invasive Ductal Carcinoma, Not Otherwise Specified","longName":"2581223","preferredDefinition":"Invasive ductal carcinoma is the most common type of invasive breast carcinoma (accounting for approximately 70% of breast carcinomas). The gross appearance is usually typical with an irregular stellate outline. Microscopically, randomly arranged epithelial elements are seen. When large sheets of malignant cells are present, necrosis may be seen. With adequate tissue sampling, in situ carcinoma can be demonstrated in association with the infiltrating carcinoma. The in situ component is nearly always ductal but occasionally may be lobular or both. --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive Breast Carcinoma of No Special Type","conceptCode":"C4194","definition":"A term that refers to a large and heterogeneous group of invasive breast carcinomas that cannot be classified morphologically as any of the special histological types. (WHO 2019)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A54-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0D9FA6B-78EC-B353-E040-BB89AD436A7F","beginDate":"2009-02-11","endDate":null,"createdBy":"CURTIST","dateCreated":"2011-11-03","modifiedBy":"ONEDATA","dateModified":"2011-11-03","deletedIndicator":"No"},{"value":"Invasive Ductal Carcinoma","valueDescription":"Invasive Carcinoma","ValueMeaning":{"publicId":"2947204","version":"1","preferredName":"Invasive Carcinoma","longName":"2947204","preferredDefinition":"A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive Carcinoma","conceptCode":"C9480","definition":"A carcinoma that is not confined to the epithelium, and has spread to the surrounding stroma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"74B8CCF7-601E-8C1B-E040-BB89AD430406","latestVersionIndicator":"Yes","beginDate":"2009-09-29","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-09-29","modifiedBy":"ONEDATA","dateModified":"2009-09-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B0D9FA6B-7917-B353-E040-BB89AD436A7F","beginDate":"2009-02-11","endDate":null,"createdBy":"CURTIST","dateCreated":"2011-11-03","modifiedBy":"ONEDATA","dateModified":"2011-11-03","deletedIndicator":"No"},{"value":"Heavy Chain Disease","valueDescription":"Heavy Chain Disease","ValueMeaning":{"publicId":"2838574","version":"1","preferredName":"Heavy Chain Disease","longName":"2838574","preferredDefinition":"One of a group of rare disorders of immunoglobulin synthesis associated with B-cell proliferative disorders and diagnosed by the finding of heavy chains in the serum, urine, or both. Heavy chains are immunologically related to the Fc fragment of the immunoglobulin chain. Three types of heavy chain disease (HCD) have been recognized: gamma heavy chain disease (associated with Waldenstrom's macroglobulinemia), alpha heavy chain disease (also known as immunoproliferative small intestinal disease or Mediterranean lymphoma), and mu heavy chain disease (associated with chronic lymphocytic leukemia). Complications of HCD vary depending upon type.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heavy Chain Disease","conceptCode":"C3082","definition":"A group of rare clonal disorders of immunoglobulin synthesis associated with B-cell proliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-5814-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-582D-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Hairy Cell Leukemia","valueDescription":"Hairy Cell Leukemia","ValueMeaning":{"publicId":"2838575","version":"1","preferredName":"Hairy Cell Leukemia","longName":"2838575","preferredDefinition":"A rare neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen and peripheral blood.  Most patients are middle-aged to elderly adults and present with splenomegaly and pancytopenia. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hairy Cell Leukemia","conceptCode":"C7402","definition":"A neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients present with splenomegaly and pancytopenia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-5837-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-5850-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Gliosarcoma","valueDescription":"Gliosarcoma","ValueMeaning":{"publicId":"2578705","version":"1","preferredName":"Gliosarcoma","longName":"2578705","preferredDefinition":"A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gliosarcoma","conceptCode":"C3796","definition":"A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-007E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-585A-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Glioblastoma","valueDescription":"Glioblastoma","ValueMeaning":{"publicId":"2578734","version":"1","preferredName":"Glioblastoma","longName":"2578734","preferredDefinition":"A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glioblastoma","conceptCode":"C3058","definition":"The most malignant astrocytic tumor (WHO grade 4).  It is composed of poorly differentiated neoplastic astrocytes and is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-009B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"ONEDATA","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-5865-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Indolent Systemic Mastocytosis","valueDescription":"Indolent Systemic Mastocytosis","ValueMeaning":{"publicId":"2838579","version":"1","preferredName":"Indolent Systemic Mastocytosis","longName":"2838579","preferredDefinition":"An indolent mast cell neoplasm characterized by systemic infiltration of skin and internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinically, there is no evidence of palpable hepatomegaly and splenomegaly, malabsorption syndrome, or pathologic fractures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indolent Systemic Mastocytosis","conceptCode":"C9286","definition":"An indolent mast cell neoplasm characterized by systemic infiltration of skin and internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinically, there is no evidence of palpable hepatomegaly and splenomegaly, malabsorption syndrome, or pathologic fractures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-58B2-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-58CB-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Hepatosplenic T-Cell Lymphoma","valueDescription":"Hepatosplenic T-Cell Lymphoma","ValueMeaning":{"publicId":"2838581","version":"1","preferredName":"Hepatosplenic T-Cell Lymphoma","longName":"2838581","preferredDefinition":"An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatosplenic T-Cell Lymphoma","conceptCode":"C8459","definition":"An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type.  It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids.  A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-58F8-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-5911-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Hemangioblastoma","valueDescription":"Capillary Hemangioblastoma","ValueMeaning":{"publicId":"2838583","version":"1","preferredName":"Capillary Hemangioblastoma","longName":"2838583","preferredDefinition":"A WHO grade I tumor of uncertain histogenesis which is composed of stromal cells and abundant capillaries. Approximately 25% of hemangioblastomas are associated with Von Hippel-Lindau disease, a disease inherited through an autosomal dominant trait and characterized by the development of capillary hemangioblastomas of the central nervous system and retina, clear cell renal carcinoma, pheochromocytoma, and pancreatic and inner ear tumors. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemangioblastoma","conceptCode":"C3801","definition":"A rare, slow-growing tumor of uncertain histogenesis. It affects the central nervous system and infrequently other sites. It is composed of stromal cells and abundant capillaries.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-591E-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-5937-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Juvenile Myelomonocytic Leukemia","valueDescription":"Juvenile Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2838584","version":"1","preferredName":"Juvenile Myelomonocytic Leukemia","longName":"2838584","preferredDefinition":"A myelodysplastic/myeloproliferative disease of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages.  Myelomonocytic proliferation is seen in the bone marrow and the blood.  The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Myelomonocytic Leukemia","conceptCode":"C9233","definition":"A clonal myeloid disorder of childhood previously classified as myelodysplastic/myeloproliferative neoplasm. It is characterized by the presence of monocytic proliferation in peripheral blood, less than 20% blasts in bone marrow and peripheral blood, splenomegaly, and the absence of BCR-ABL1 fusion. Almost all patients carry mutations of the RAS pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-5942-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-595B-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Invasive Ductal Carcinoma With Extensive Intraductal Component","valueDescription":"Invasive Ductal Breast Carcinoma with Predominant Intraductal Component","ValueMeaning":{"publicId":"2577195","version":"1","preferredName":"Invasive Ductal Breast Carcinoma with Predominant Intraductal Component","longName":"2577195","preferredDefinition":"A breast carcinoma characterized by the presence of a predominant ductal carcinoma in situ component and a minor component of invasive carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive Breast Carcinoma of No Special Type with Predominant Intraductal Component","conceptCode":"C9132","definition":"An invasive breast carcinoma of no special type characterized by the presence of a predominant ductal carcinoma in situ component and a minor component of invasive carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA98-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-09","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"DWARZEL","dateModified":"2006-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-596F-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Interdigitating Dendritic Cell Sarcoma or Tumor","valueDescription":"Interdigitating Dendritic Cell Sarcoma/Tumor","ValueMeaning":{"publicId":"2838586","version":"1","preferredName":"Interdigitating Dendritic Cell Sarcoma/Tumor","longName":"2838586","preferredDefinition":"A neoplastic proliferation of spindle to ovoid cells which show phenotypic features similar to those of interdigitating dendritic cells.  The clinical course is variable ranging from benign localized disease to widespread lethal disease. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Interdigitating Dendritic Cell Sarcoma","conceptCode":"C9282","definition":"A neoplastic proliferation of spindle to ovoid cells which show phenotypic features similar to those of interdigitating dendritic cells.  The clinical course is generally aggressive. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-59A7-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A51A25-59C0-CA49-E040-BB89AD435D3A","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Yolk Sac Tumor","valueDescription":"Yolk Sac Tumor","ValueMeaning":{"publicId":"2838868","version":"1","preferredName":"Yolk Sac Tumor","longName":"2838868","preferredDefinition":"This is the most common malignant germ cell tumor in the pediatric population. Yolk sac tumors arise in the infant testis, ovary, sacrococcygeal region, vagina, uterus, prostate, abdomen, liver, retroperitoneum, thorax and pineal/third ventricle. The tumor mimics the yolk sac of the embryo and produces alpha-fetoprotein (AFP). Treatment includes: surgical resection, radiation and chemotherapy. This tumor is very responsive to chemotherapy regimens that include cisplatinum. - 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yolk Sac Tumor","conceptCode":"C3011","definition":"A non-seminomatous malignant germ cell tumor composed of primitive germ cells.  It is the most common malignant germ cell tumor in the pediatric population. It occurs in the infant testis, ovary, sacrococcygeal region, vagina, uterus, prostate, abdomen, liver, retroperitoneum, thorax, and pineal/third ventricle. The tumor mimics the yolk sac of the embryo and produces alpha-fetoprotein (AFP). Treatment includes: surgical resection, radiation, and chemotherapy. This tumor is very responsive to chemotherapy regimens that include cisplatinum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A9E389-584E-FD59-E040-BB89AD432A90","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A9E389-5867-FD59-E040-BB89AD432A90","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Undifferentiated Carcinoma With Osteoclast-Like Giant Cells","valueDescription":"Undifferentiated Carcinoma with Osteoclast-Like Giant Cells","ValueMeaning":{"publicId":"2838870","version":"1","preferredName":"Undifferentiated Carcinoma with Osteoclast-Like Giant Cells","longName":"2838870","preferredDefinition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular or squamous differentiation and giant cells resembling osteoclasts.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated Carcinoma with Osteoclast-Like Giant Cells","conceptCode":"C63622","definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular or squamous differentiation and giant cells resembling osteoclasts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A9E389-5874-FD59-E040-BB89AD432A90","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A9E389-588D-FD59-E040-BB89AD432A90","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Undifferentiated Carcinoma - NOS","valueDescription":"Undifferentiated Carcinoma","ValueMeaning":{"publicId":"2838871","version":"1","preferredName":"Undifferentiated Carcinoma","longName":"2838871","preferredDefinition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated Carcinoma","conceptCode":"C3692","definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A9E389-5897-FD59-E040-BB89AD432A90","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A9E389-58B0-FD59-E040-BB89AD432A90","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Unclassified Renal Cell Carcinoma","valueDescription":"Unclassified Renal Cell Carcinoma","ValueMeaning":{"publicId":"2838873","version":"1","preferredName":"Unclassified Renal Cell Carcinoma","longName":"2838873v1.00","preferredDefinition":"A renal cell carcinoma characterized by morphologic features that do not fit easily into one of the other well-defined categories of renal cell carcinoma. Examples of such features include mixtures of morphologic patterns, mucin production, and sarcomatoid morphology.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unclassified Renal Cell Carcinoma","conceptCode":"C27892","definition":"A renal cell carcinoma characterized by morphologic features that do not fit easily into one of the other well-defined categories of renal cell carcinoma. Examples of such features include mixtures of morphologic patterns, mucin production, and sarcomatoid morphology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A9E389-58BD-FD59-E040-BB89AD432A90","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A9E389-58D6-FD59-E040-BB89AD432A90","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Tubular","valueDescription":"Tubular","ValueMeaning":{"publicId":"2838874","version":"1","preferredName":"Tubular","longName":"2838874","preferredDefinition":"shaped like a tube; of or pertaining to a tubule. (On-line Medical Dictionary)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tubular","conceptCode":"C14169","definition":"Shaped like a tube; of or pertaining to a tubule.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A9E389-58E0-FD59-E040-BB89AD432A90","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A9E389-58F9-FD59-E040-BB89AD432A90","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"AML With t(8;21)(q22;q22)","valueDescription":"Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1","ValueMeaning":{"publicId":"2672720","version":"1","preferredName":"Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1","longName":"2672720","preferredDefinition":"An acute myeloid leukemia with t(8;21)(q22;q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with t(8;21)(q22; q22.1); RUNX1-RUNX1T1","conceptCode":"C9288","definition":"An acute myeloid leukemia with t(8;21)(q22; q22.1) giving rise to RUNX1/RUNX1T1 fusion transcript and showing maturation in the neutrophil lineage. The bone marrow and the peripheral blood show large myeloblasts with abundant basophilic cytoplasm, often containing azurophilic granules. This type of AML is associated with good response to chemotherapy and high complete remission rate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37BBBFE3-F172-60D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition and VM Long Name_ghd_11.16.16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"628169CF-8367-F4D3-E040-BB89AD433D78","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Astrocytoma - Pleomorphic Xanthoastrocytoma","valueDescription":"Pleomorphic Xanthoastrocytoma","ValueMeaning":{"publicId":"2578698","version":"1","preferredName":"Pleomorphic Xanthoastrocytoma","longName":"2578698","preferredDefinition":"Pleomorphic Xanthoastrocytoma is an astrocytic tumor with a relatively favorable prognosis (WHO grade II) and is typically encountered in children and young adults. It has a superficial location in the cerebral hemispheres and involvement of the meninges. Characteristic features include pleomorphic and lipidized cells expressing GFAP and often surrounded by a reticulin network as well as eosinophilic granular bodies. For lesions with significant mitotic activity (5 or more mitoses per 10 HPF) and/or with areas of necrosis, the designation \"pleomorphic xanthoastrocytoma with anaplastic features\" may be used. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleomorphic Xanthoastrocytoma","conceptCode":"C4323","definition":"A WHO grade 2 astrocytic tumor with a relatively favorable prognosis.  It is characterized by pleomorphic and lipidized cells expressing GFAP often surrounded by a reticulin network and eosinophilic granular bodies. It presents in the superficial cerebral hemispheres and involves the meninges. It typically affects children and young adults.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0077-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"628169CF-837D-F4D3-E040-BB89AD433D78","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Astrocytoma - Pilocytic","valueDescription":"Pilocytic astrocytoma","ValueMeaning":{"publicId":"2578708","version":"1","preferredName":"Pilocytic astrocytoma","longName":"2578708","preferredDefinition":"Pilocytic Astrocytoma, the most common glioma in children, is a WHO grade I astrocytic tumor. It is a generally well circumscribed, slowly growing, often cystic, astrocytoma. It is histologically characterized by a biphasic pattern with varying proportion of compacted bipolar cells which may have Rosenthal fibers (tapered corkscrew-shaped, brightly eosinophilic, intracytoplasmic hyaline masses) and loose textured multipolar cells with microcysts and granular bodies. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pilocytic Astrocytoma","conceptCode":"C4047","definition":"A WHO grade 1, relatively circumscribed, slowly growing, often cystic astrocytoma occurring in children and young adults.  Histologically it is characterized by a biphasic pattern with compacted bipolar cells associated with Rosenthal fibers and multipolar cells associated with microcysts and eosinophilic bodies/hyaline droplets. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0081-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"628169CF-8392-F4D3-E040-BB89AD433D78","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Essential Thrombocythemia","valueDescription":"Essential Thrombocythemia","ValueMeaning":{"publicId":"2838061","version":"1","preferredName":"Essential Thrombocythemia","longName":"2838061","preferredDefinition":"A chronic myeloproliferative disorder that involves primarily the megakaryocytic lineage and it is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage.  The cause is unknown.  Median survival times of 10-15 years are commonly reported.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Essential Thrombocythemia","conceptCode":"C3407","definition":"A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62843923-FF56-E9AE-E040-BB89AD435A7B","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62843923-FF6F-E9AE-E040-BB89AD435A7B","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Collecting Duct Carcinoma","valueDescription":"Carcinoma of the Collecting Ducts of Bellini","ValueMeaning":{"publicId":"2581666","version":"1","preferredName":"Carcinoma of the Collecting Ducts of Bellini","longName":"2581666","preferredDefinition":"Also known as collecting duct carcinoma, this is a rare type of renal carcinoma. It arises from the collecting ducts of the renal medulla, and most authors suggest that this is an aggressive tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Collecting Duct Carcinoma","conceptCode":"C6194","definition":"Also known as collecting duct carcinoma, this is a rare type of renal carcinoma. It arises from the collecting ducts of the renal medulla, and most authors suggest that this is an aggressive tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C0F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-09","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-09","modifiedBy":"COOPERM","dateModified":"2020-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-8409-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Clear Cell Renal Carcinoma","valueDescription":"Conventional (Clear Cell) Renal Cell Carcinoma","ValueMeaning":{"publicId":"2581625","version":"1","preferredName":"Conventional (Clear Cell) Renal Cell Carcinoma","longName":"2581625","preferredDefinition":"A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network.  The tumor may metastasize to unusual sites and late metastasis is common.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clear Cell Renal Cell Carcinoma","conceptCode":"C4033","definition":"A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network.  The tumor may metastasize to unusual sites and late metastasis is common.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0BE6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-07","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-07","modifiedBy":"ONEDATA","dateModified":"2006-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-841E-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Classical Hodgkin Lymphoma","valueDescription":"Classical Hodgkin Lymphoma","ValueMeaning":{"publicId":"2838033","version":"1","preferredName":"Classical Hodgkin Lymphoma","longName":"2838033","preferredDefinition":"In more than 95% of cases, a monoclonal B-cell lymphoproliferation characterized by a bimodal age distribution (15-30 years of life and late life), often associated with EBV infection.  In less than 5% of cases, this is a monoclonal proliferation of T-lymphocytes. Morphologically, it is characterized by the presense of Reed-Sternberg cells and mononuclear Hodgkin cells.  The Reed-Sternberg and mononuclear Hodgkin cells are CD30 positive in nearly all cases and CD15 positive in the majority of cases.  -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classic Hodgkin Lymphoma","conceptCode":"C7164","definition":"A category of Hodgkin lymphomas that includes the following four histologic subtypes: lymphocyte-rich, nodular sclerosis, mixed cellularity, and lymphocyte-depleted classic Hodgkin lymphoma. The vast majority of Hodgkin lymphomas belong to this category.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-842C-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-8445-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Craniopharyngioma - Papillary","valueDescription":"Papillary Craniopharyngioma","ValueMeaning":{"publicId":"2838035","version":"1","preferredName":"Papillary Craniopharyngioma","longName":"2838035","preferredDefinition":"A craniopharyngioma composed of sheets of squamous epithelium which separate to form pseudopapillae. This variant typically lacks nuclear palisading, wet keratin, calcification, and cholesterol deposits. Clinically, endocrine deficiencies are more often associated with papillary craniopharyngioma than with the adamantinomatous type. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Craniopharyngioma","conceptCode":"C4725","definition":"A craniopharyngioma composed of sheets of squamous epithelium which separate to form pseudopapillae. This variant typically lacks nuclear palisading, wet keratin, calcification, and cholesterol deposits. Clinically, endocrine deficiencies are more often associated with papillary craniopharyngioma than with the adamantinomatous type. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-8453-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-846C-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Craniopharyngioma - Adamantinomatous","valueDescription":"Adamantinous Craniopharyngioma","ValueMeaning":{"publicId":"2578731","version":"1","preferredName":"Adamantinous Craniopharyngioma","longName":"2578731","preferredDefinition":"Adamantinomatous Craniopharyngioma consists of broad strands, cords and bridges of a multistratified squamous epithelium with peripheral palisading of nuclei. Diagnostic features include nodules of compact 'wet' keratin and dystrophic calcification. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adamantinomatous Craniopharyngioma","conceptCode":"C4726","definition":"A craniopharyngioma consisting of broad strands, cords and bridges of a multistratified squamous epithelium with peripheral palisading of nuclei. Diagnostic features include nodules of compact 'wet' keratin and dystrophic calcification. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0098-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-8480-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Desmoplastic (spindle Desmoplastic - neuroid) melanoma","valueDescription":"Desmoplastic Melanoma","ValueMeaning":{"publicId":"2581228","version":"1","preferredName":"Desmoplastic Melanoma","longName":"2581228","preferredDefinition":"A melanoma of the skin characterized by a proliferation of atypical spindled melanocytes in the dermis, in a background of abundant collagen. It usually presents as an amelanotic raised nodular lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desmoplastic Melanoma","conceptCode":"C37257","definition":"A melanoma of the skin characterized by a proliferation of atypical spindled melanocytes in the dermis, in a background of abundant collagen. It usually presents as an amelanotic raised nodular lesion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A59-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-8496-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Dendritic Cell Sarcoma - NOS","valueDescription":"Dendritic Cell Sarcoma, not Otherwise Specified","ValueMeaning":{"publicId":"2838036","version":"1","preferredName":"Dendritic Cell Sarcoma, not Otherwise Specified","longName":"2838036","preferredDefinition":"A dendritic cell neoplasm that does not fall into well-defined categories.  Such tumors have been called indeterminate cell sarcomas.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dendritic Cell Tumor, Not Otherwise Specified","conceptCode":"C27260","definition":"A dendritic cell neoplasm that does not fall into well-defined categories or shows hybrid features.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-84A1-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-84BA-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Cribriform","valueDescription":"Cribriform","ValueMeaning":{"publicId":"2738823","version":"1","preferredName":"Cribriform","longName":"2738823","preferredDefinition":"Cribriform; having the appearance of a sieve: containing many perforations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cribriform","conceptCode":"C25731","definition":"Having the appearance of a sieve: containing many perforations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49F8B2D6-A86D-712E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"JONSDOTTIRT","dateCreated":"2008-04-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-84C4-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Ductal Carcinoma In Situ","valueDescription":"Ductal Breast Carcinoma In Situ","ValueMeaning":{"publicId":"2581232","version":"1","preferredName":"Ductal Breast Carcinoma In Situ","longName":"2581232","preferredDefinition":"Ductal carcinoma in situ (DCIS) is a carcinoma entirely confined to the mammary ducts. There is no evidence of invasion of the basement membrane. Currently, DCIS is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS. --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Ductal Carcinoma In Situ","conceptCode":"C2924","definition":"A breast carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-84DA-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Ductal Adenocarcinoma","valueDescription":"Ductal Breast Carcinoma","ValueMeaning":{"publicId":"2838039","version":"1","preferredName":"Ductal Breast Carcinoma","longName":"2838039","preferredDefinition":"A carcinoma arising from the ducts.  While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast.  Ductal carcinomas account for about two thirds of all breast cancers.  Two types of ductal carcinomas have been described: Ductal carcinoma in situ (DCIS) and invasive ductal carcinoma, not otherwise specified.  The latter often spreads to the axillary lymph nodes and other anatomic sites.  The two forms of ductal carcinoma often coexist.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Ductal Carcinoma","conceptCode":"C4017","definition":"A breast carcinoma arising from the ducts.  While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast. Ductal carcinomas account for about two thirds of all breast cancers. Two types of ductal carcinomas have been described: ductal carcinoma in situ (DCIS) and invasive breast carcinoma of no special type. The latter often spreads to the axillary lymph nodes and other anatomic sites. The two forms of ductal carcinoma often coexist.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-84E7-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-8500-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Diffuse Large B-Cell Lymphoma","valueDescription":"Diffuse Large B-Cell Lymphoma","ValueMeaning":{"publicId":"2838040","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma","longName":"2838040","preferredDefinition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma","conceptCode":"C8851","definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-850A-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SOKKERL","dateModified":"2018-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-8523-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Enteropathy-Type T-Cell Lymphoma","valueDescription":"Enteropathy-type T-Cell Lymphoma","ValueMeaning":{"publicId":"2838043","version":"1","preferredName":"Enteropathy-type T-Cell Lymphoma","longName":"2838043","preferredDefinition":"An uncommon mature T-cell lymphoma of intraepithelial lymphocytes.  It usually arises from the small intestine, most commonly the jejunum or ileum.  Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract.  It is seen with increased frequency in regions with a high prevalence of celiac disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Enteropathy-Associated T-Cell Lymphoma","conceptCode":"C4737","definition":"A mature T-cell and NK-cell non-Hodgkin lymphoma of intraepithelial T-lymphocytes. It usually arises from the small intestine, most commonly the jejunum or ileum.  Other less frequent primary anatomic sites include the duodenum, stomach, colon, or outside the gastrointestinal tract. It is characterized by the presence of pleomorphic medium-sized to large T-lymphocytes with vesicular nuclei, prominent nucleoli, and moderate to abundant pale cytoplasm. It is associated with celiac disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-852E-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-8547-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Embryonal Carcinoma","valueDescription":"Embryonal Carcinoma","ValueMeaning":{"publicId":"2838044","version":"1","preferredName":"Embryonal Carcinoma","longName":"2838044","preferredDefinition":"A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Embryonal Carcinoma","conceptCode":"C3752","definition":"A non-seminomatous malignant germ cell tumor characterized by the presence of large germ cells with abundant cytoplasm resembling epithelial cells, geographic necrosis, high mitotic activity, and pseudoglandular and pseudopapillary structures formation. It can arise from the testis, ovary, and extragonadal sites (central nervous system and mediastinum).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-8551-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62837FF7-856A-6F46-E040-BB89AD433964","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Ependymoma - Myxopapillary","valueDescription":"Myxopapillary ependymoma","ValueMeaning":{"publicId":"2578709","version":"1","preferredName":"Myxopapillary ependymoma","longName":"2578709","preferredDefinition":"Myxopapillary Ependymomas (WHO grade I) are slow growing gliomas which generally occur in young adults and arise almost exclusively in the conus-cauda-filum terminale region. It generally has a favorable prognosis and is characterized histologically by tumor cells arranged in a papillary manner around vascularized mucoid stromal cores. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myxopapillary Ependymoma","conceptCode":"C3697","definition":"A slow growing, WHO grade I glioma which generally occurs in young adults.  It arises almost exclusively in the conus medullaris, cauda equina, and filum terminale of the spinal cord. It generally has a favorable prognosis and is characterized histologically by tumor cells arranged in a papillary manner around vascularized mucoid stromal cores. (Adapted from WHO).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0082-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62843923-FEF4-E9AE-E040-BB89AD435A7B","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Ependymoma - Anaplastic","valueDescription":"Anaplastic ependymoma","ValueMeaning":{"publicId":"2572931","version":"1","preferredName":"Anaplastic ependymoma","longName":"2572931","preferredDefinition":"Anaplastic Ependymoma (WHO grade III) is a malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. Anaplastic Ependymomas show high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Ependymoma","conceptCode":"C4049","definition":"A WHO grade 3 malignant glioma of ependymal origin with accelerated growth and an unfavorable clinical outcome, particularly in children. It is characterized by high mitotic activity, often accompanied by microvascular proliferation and pseudo-palisading necrosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9F0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62843923-FF09-E9AE-E040-BB89AD435A7B","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Extranodal NK or T-Cell Lymphoma - Nasal Type","valueDescription":"Nasal Type Extranodal NK/T-Cell Lymphoma","ValueMeaning":{"publicId":"2593089","version":"1","preferredName":"Nasal Type Extranodal NK/T-Cell Lymphoma","longName":"2593089","preferredDefinition":"An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma.  It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells.  The nasal cavity is the commonest site of involvement.  Patients often present with midfacial destructive lesions (lethal midline granuloma).  The disease may disseminate rapidly to various anatomic sites including gastrointestinal tract, skin, testis, and cervical lymph nodes.  It is also known as angiocentric T-cell lymphoma.  The term \"polymorphic reticulosis\" has been widely used to describe the morphologic changes seen in this type of lymphoma.  However, the latter term may also apply to lymphomatoid granulomatosis which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasal Type Extranodal NK/T-Cell Lymphoma","conceptCode":"C4684","definition":"An aggressive, predominantly extranodal, mature T-cell non-Hodgkin lymphoma. It is characterized by an often angiocentric and angiodestructive cellular infiltrate composed of EBV positive NK/T cells. The nasal cavity is the most common site of involvement. Patients often present with midfacial destructive lesions (lethal midline granuloma). The disease may disseminate rapidly to various anatomic sites including the gastrointestinal tract, skin, testis, and cervical lymph nodes. It is also known as angiocentric T-cell lymphoma. The term \"polymorphic reticulosis\" has been widely used to describe the morphologic changes seen in this type of lymphoma. However, the latter term may also apply to lymphomatoid granulomatosis, which is an angiocentric and angiodestructive EBV positive B-cell lymphoproliferative disorder.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286BA529-8F3E-7325-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62843923-FF36-E9AE-E040-BB89AD435A7B","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Extranodal Marginal Zone B-Cell Lymphoma Of Mucosa-Associated Lymphoid Tissue (MALT-Lymphoma)","valueDescription":"Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue","ValueMeaning":{"publicId":"2593078","version":"1","preferredName":"Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue","longName":"2593078","preferredDefinition":"MALT lymphoma.  A type of cancer that arises in cells in mucosal tissue that are involved in antibody production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","conceptCode":"C3898","definition":"An indolent, extranodal type of non-Hodgkin lymphoma composed of small B-lymphocytes (centrocyte-like cells).  The gastrointestinal tract is the most common site of involvement.  Other common sites of involvement include lung, head and neck, ocular adnexae, skin, thyroid, and breast.  Gastric involvement is associated with the presence of H. pylori infection. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A14-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62843923-FF4B-E9AE-E040-BB89AD435A7B","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Ependymoma - Tanycytic","valueDescription":"Tanycytic Ependymoma","ValueMeaning":{"publicId":"2838063","version":"1","preferredName":"Tanycytic Ependymoma","longName":"2838063","preferredDefinition":"A variant of Ependymoma, often found in the spinal cord, with tumor cells arranged in fascicles of variable width and cell density. Ependymal rosettes are generally absent, so this lesion must be distinguished from astrocytic neoplasms, but its EM characteristics are ependymal. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tanycytic Ependymoma","conceptCode":"C6903","definition":"A variant of ependymoma, often found in the spinal cord, with tumor cells arranged in fascicles of variable width and cell density. Ependymal rosettes are generally absent, so this lesion must be distinguished from astrocytic neoplasms, but its EM characteristics are ependymal. (Adapted from WHO.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62843923-FF7C-E9AE-E040-BB89AD435A7B","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62843923-FF95-E9AE-E040-BB89AD435A7B","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Myeloproliferative Disease - Unclassifiable","valueDescription":"Myelodysplastic/Myeloproliferative Disease, Unclassifiable","ValueMeaning":{"publicId":"2838632","version":"1","preferredName":"Myelodysplastic/Myeloproliferative Disease, Unclassifiable","longName":"2838632","preferredDefinition":"This entity includes cases that have clinical, laboratory, and morphologic features that support the diagnosis of both a myelodysplastic syndrome and a chronic myeloproliferative disorder, but do not meet the criteria for any of the other entities included in the myelodysplastic/myeloproliferative disease category.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified","conceptCode":"C27780","definition":"A myelodysplastic/myeloproliferative neoplasm that does not meet the criteria of other myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, and myeloproliferative neoplasms. It is associated with cytopenia, blasts less than 20% in bone marrow and peripheral blood, thrombocytosis, and absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-B1A0-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C37E5C-AAB1-885F-E040-BB89AD4309BC","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Mucinous Noncystic Carcinoma","valueDescription":"Pancreatic Mucinous Noncystic Carcinoma","ValueMeaning":{"publicId":"2581789","version":"1","preferredName":"Pancreatic Mucinous Noncystic Carcinoma","longName":"2581789","preferredDefinition":"A pancreatic adenocarcinoma, clinicopathologically distinct from conventional pancreatic ductal adenocarcinomas, with a relatively indolent behavior (5-year survival of 55%).  It often arises in association with intraductal pancreatic mucinous neoplasms. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Colloid Carcinoma","conceptCode":"C37214","definition":"An infiltrating pancreatic ductal adenocarcinoma, characterized by the presence of malignant cells floating in pools of mucin.  It has a more favorable prognosis than the conventional infiltrating ductal adenocarcinoma.  It often arises in association with intraductal pancreatic mucinous neoplasms and in some cases it may result in the development of pseudomyxoma peritonei.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C8A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C55BD4-28A2-B48D-E040-BB89AD432C7E","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Typical Carcinoid Tumor","valueDescription":"Convention Carcinoid Tumor","ValueMeaning":{"publicId":"2861491","version":"1","preferredName":"Convention Carcinoid Tumor","longName":"2861491","preferredDefinition":"Something regarded as a normative example.: Carcinoid tumor, also known as well differentiated endocrine neoplasm, is a slow growing neuroendocrine tumor, composed of uniform, round, or polygonal cells having monotonous, centrally located nuclei and small nucleoli, infrequent mitoses, and no necrosis.  The tumor may show a variety of patterns, such as solid, trabecular, and acinar.  Electron microscopy shows small secretory granules.  Immunohistochemical studies reveal NSE, as well as chromogranin immunoreactivity.  Malignant histology (cellular pleomorphism, hyperchromatic nuclei, prominent nucleoli, necrosis, and mitoses) can occasionally be seen.  Such cases may have an aggressive clinical course.  Gastrointestinal tract and lung are common sites of involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Convention","conceptCode":"C61300","definition":"Something regarded as a normative example.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoid Tumor","conceptCode":"C2915","definition":"A slow growing neuroendocrine tumor, composed of uniform, round, or polygonal cells having monotonous, centrally located nuclei and small nucleoli, infrequent mitoses, and no necrosis.  The tumor may show a variety of patterns, such as solid, trabecular, and acinar.  Electron microscopy shows small secretory granules.  Immunohistochemical studies reveal NSE, as well as chromogranin immunoreactivity.  Malignant histology (cellular pleomorphism, hyperchromatic nuclei, prominent nucleoli, necrosis, and mitoses) can occasionally be seen.  Such cases may have an aggressive clinical course.  Gastrointestinal tract and lung are common sites of involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C55BD4-28D6-B48D-E040-BB89AD432C7E","latestVersionIndicator":"Yes","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C55BD4-28EF-B48D-E040-BB89AD432C7E","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Secretory (Juvenile)","valueDescription":"Juvenile Lesion Secretory Cell","ValueMeaning":{"publicId":"2861492","version":"1","preferredName":"Juvenile Lesion Secretory Cell","longName":"2861492","preferredDefinition":"A benign or malignant lesion typically arising in the period between infancy and adulthood.: One of several types of cells that generate and secrete a substance to be used by the organism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Lesion","conceptCode":"C62226","definition":"A benign or malignant lesion typically arising in the period between infancy and adulthood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Secretory Cell","conceptCode":"C13055","definition":"One of several types of cells that generate and secrete a substance to be used by the organism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67C55BD4-28FC-B48D-E040-BB89AD432C7E","latestVersionIndicator":"Yes","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67C55BD4-2915-B48D-E040-BB89AD432C7E","beginDate":"2009-04-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-17","modifiedBy":"ONEDATA","dateModified":"2009-04-17","deletedIndicator":"No"},{"value":"Mucinous Cystadenocarcinoma - invasive","valueDescription":"Invasive Mucinous Cystadenocarcinoma","ValueMeaning":{"publicId":"2861411","version":"1","preferredName":"Invasive Mucinous Cystadenocarcinoma","longName":"2861411","preferredDefinition":"Marked by a tendency to spread especially into healthy tissue.: An invasive adenocarcinoma characterized by cystic changes and the presence of malignant glandular cells which contain intracytoplasmic mucin. It may arise from the ovary, pancreas, appendix, and lung.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Invasive","conceptCode":"C14159","definition":"Marked by a tendency to spread, especially into healthy surrounding tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mucinous Cystadenocarcinoma","conceptCode":"C3776","definition":"An invasive adenocarcinoma characterized by cystic changes and the presence of malignant glandular cells which contain intracytoplasmic mucin. It may arise from the ovary, pancreas, appendix, and lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B13250-52D4-3FB8-E040-BB89AD43483F","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67B13250-52ED-3FB8-E040-BB89AD43483F","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Mucinous (Colloid) Adenocarcinoma","valueDescription":"Mucinous Adenocarcinoma","ValueMeaning":{"publicId":"2838623","version":"1","preferredName":"Mucinous Adenocarcinoma","longName":"2838623","preferredDefinition":"An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucinous Adenocarcinoma","conceptCode":"C26712","definition":"An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-596B-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"HARTLEYG","dateModified":"2017-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67B13250-5301-3FB8-E040-BB89AD43483F","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Meningioma - Other","valueDescription":"Other Meningioma","ValueMeaning":{"publicId":"2861412","version":"1","preferredName":"Other Meningioma","longName":"2861412","preferredDefinition":"Not otherwise specified.: Meningiomas (mostly WHO grade I, with some WHO grade II or III) are generally slow growing, benign tumors attached to the dura mater and are composed of neoplastic meningothelial (arachnoidal) cells. They typically occur in adults, often women. Meningiomas have a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Meningioma","conceptCode":"C3230","definition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade 1 tumors, and some are WHO grade 2 or 3 tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B13250-530E-3FB8-E040-BB89AD43483F","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67B13250-5327-3FB8-E040-BB89AD43483F","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Melanoma In Congenital Melanocytic Nevi","valueDescription":"Melanoma in Congenital Melanocytic Nevus","ValueMeaning":{"publicId":"2861413","version":"1","preferredName":"Melanoma in Congenital Melanocytic Nevus","longName":"2861413v1.00","preferredDefinition":"A melanoma of the skin arising from a congenital melanocytic nevus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma in Congenital Melanocytic Nevus","conceptCode":"C48613","definition":"A melanoma of the skin arising from a congenital melanocytic nevus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B13250-5331-3FB8-E040-BB89AD43483F","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67B13250-534A-3FB8-E040-BB89AD43483F","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Medulloblastoma - Other","valueDescription":"Other Medulloblastoma","ValueMeaning":{"publicId":"2861414","version":"1","preferredName":"Other Medulloblastoma","longName":"2861414","preferredDefinition":"Not otherwise specified.: A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Medulloblastoma","conceptCode":"C3222","definition":"A malignant, invasive embryonal neoplasm arising from the cerebellum or posterior fossa. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: classic medulloblastoma, large cell/anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B13250-5357-3FB8-E040-BB89AD43483F","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67B13250-5370-3FB8-E040-BB89AD43483F","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Medulloblastoma - Not Otherwise Characterized","valueDescription":"Not Otherwise Specified Medulloblastoma","ValueMeaning":{"publicId":"2861415","version":"1","preferredName":"Not Otherwise Specified Medulloblastoma","longName":"2861415","preferredDefinition":"Not characterized in any other way.: A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Medulloblastoma","conceptCode":"C3222","definition":"A malignant, invasive embryonal neoplasm arising from the cerebellum or posterior fossa. It occurs predominantly in children and has the tendency to metastasize via the cerebrospinal fluid pathways. Signs and symptoms include truncal ataxia, disturbed gait, lethargy, headache, and vomiting. There are four histologic variants: classic medulloblastoma, large cell/anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B13250-537D-3FB8-E040-BB89AD43483F","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67B13250-5396-3FB8-E040-BB89AD43483F","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Malignant Perpheral Nerve Sheath Tumor (MPNST) - Other","valueDescription":"Other Malignant Peripheral Nerve Sheath Tumor","ValueMeaning":{"publicId":"2861416","version":"1","preferredName":"Other Malignant Peripheral Nerve Sheath Tumor","longName":"2861416","preferredDefinition":"Not otherwise specified.: An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Peripheral Nerve Sheath Tumor","conceptCode":"C3798","definition":"An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B13250-53A3-3FB8-E040-BB89AD43483F","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67B13250-53BC-3FB8-E040-BB89AD43483F","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Malignant Neoplasm - Type Cannot Be Determined","valueDescription":"Type Indeterminate Malignant Neoplasm","ValueMeaning":{"publicId":"2861417","version":"1","preferredName":"Type Indeterminate Malignant Neoplasm","longName":"2861417","preferredDefinition":"Type; a subdivision of a particular kind of thing.: Cannot distinguish between two or more possible values in the current context.: A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Indeterminate","conceptCode":"C48658","definition":"Cannot distinguish between two or more possible values in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B13250-53CA-3FB8-E040-BB89AD43483F","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67B13250-53E3-3FB8-E040-BB89AD43483F","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Large Cell Undifferentiated Carcinoma","valueDescription":"Undifferentiated Large Cell Carcinoma","ValueMeaning":{"publicId":"2861418","version":"1","preferredName":"Undifferentiated Large Cell Carcinoma","longName":"2861418","preferredDefinition":"A term used to describe cells or tissues that do not have specialized (\"mature\") structures or functions. Undifferentiated cancer cells often grow and spread quickly.: These represent the least common histologic subtype of lung cancers comprising approximately 15% of all lung cancers.  The frequency is decreasing with improved classification through refined histopathological analysis of these tumors as poorly differentiated squamous cell carcinomas or adenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated","conceptCode":"C14176","definition":"Describes tumor cells that generally have lost all of the appearance of normal cells. They tend to grow and spread quickly and aggressively.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Large Cell Carcinoma","conceptCode":"C3780","definition":"A malignant epithelial neoplasm composed of large, atypical cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B13250-53F0-3FB8-E040-BB89AD43483F","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67B13250-5409-3FB8-E040-BB89AD43483F","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Medullary Carcinoma","valueDescription":"Thyroid Gland Medullary Carcinoma","ValueMeaning":{"publicId":"2861420","version":"1","preferredName":"Thyroid Gland Medullary Carcinoma","longName":"2861420","preferredDefinition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland.  It is closely associated with multiple endocrine neoplasia syndromes.  Approximately 10% to 20% of medullary thyroid carcinomas are familial.  Patients usually present with a thyroid nodule that is painless and firm.  In the majority of cases nodal involvement is present at diagnosis.  Surgery is the preferred treatment for both primary lesions and recurrences.  This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.  - 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Medullary Carcinoma","conceptCode":"C3879","definition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis. Surgery is the preferred treatment for both primary lesions and recurrences. This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B13250-5416-3FB8-E040-BB89AD43483F","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"67B13250-542F-3FB8-E040-BB89AD43483F","beginDate":"2009-02-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia - Minimally Differentiated","valueDescription":"Acute Myeloid Leukemia, Minimally Differentiated","ValueMeaning":{"publicId":"2836807","version":"1","preferredName":"Acute Myeloid Leukemia, Minimally Differentiated","longName":"2836807","preferredDefinition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry.  The myeloid origin of the blasts is demonstrated by immunohistochemistry and/or electron microscopic studies.  The patients present with anemia, neutropenia, and thrombocytopenia.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Minimal Differentiation","conceptCode":"C8460","definition":"An acute myeloid leukemia (AML) in which the blasts do not show evidence of myeloid differentiation by morphology and conventional cytochemistry. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246291A-4BDF-4EA6-E040-BB89AD432443","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6246291A-4BF8-4EA6-E040-BB89AD432443","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia - Not Otherwise Characterized","valueDescription":"Acute Myeloid Leukemia not Otherwise Categorized","ValueMeaning":{"publicId":"2590754","version":"1","preferredName":"Acute Myeloid Leukemia not Otherwise Categorized","longName":"2590754","preferredDefinition":"Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  This category includes entities classified according to the French-American-British classification scheme.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia Not Otherwise Specified","conceptCode":"C27753","definition":"Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related.  This category includes entities classified according to the French-American-British classification scheme.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F3CBD2-04A7-469E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6246291A-4BB1-4EA6-E040-BB89AD432443","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia - Myeloid Sarcoma","valueDescription":"Myeloid Sarcoma","ValueMeaning":{"publicId":"2836806","version":"1","preferredName":"Myeloid Sarcoma","longName":"2836806","preferredDefinition":"A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid Sarcoma","conceptCode":"C3520","definition":"A tumor mass composed of myeloblasts or immature myeloid cells.  It occurs in extramedullary sites or the bone.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246291A-4BBC-4EA6-E040-BB89AD432443","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6246291A-4BD5-4EA6-E040-BB89AD432443","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Bronchioloalveolar Carcinoma","valueDescription":"Bronchioloalveolar Carcinoma","ValueMeaning":{"publicId":"2837829","version":"1","preferredName":"Bronchioloalveolar Carcinoma","longName":"2837829","preferredDefinition":"A well or moderately differentiated morphologic variant of lung adenocarcinoma characterized by tumor growth along the alveolar structures without stromal, vascular, or pleural invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minimally Invasive Lung Adenocarcinoma","conceptCode":"C2923","definition":"A solitary adenocarcinoma arising from the lung and measuring 3 cm or less in size. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-47D8-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6281C75A-47F1-A127-E040-BB89AD431A41","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"B-Cell Prolymphocytic Leukemia","valueDescription":"B-Cell Prolymphocytic Leukemia","ValueMeaning":{"publicId":"2837830","version":"1","preferredName":"B-Cell Prolymphocytic Leukemia","longName":"2837830","preferredDefinition":"A malignant B-cell lymphoproliferative process affecting the blood, bone marrow, and spleen.  The B-prolymphocytes are medium-sized, round lymphoid cells with prominent nucleoli.  The B-prolymphocytes must exceed 55% of lymphoid cells in the blood.  Cases of transformed chronic lymphocytic leukemia (CLL) and CLL with increased prolymphocytes are excluded.  The prognosis is poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B-Cell Prolymphocytic Leukemia","conceptCode":"C4753","definition":"A malignant B-cell lymphoproliferative process affecting the blood, bone marrow, and spleen.  The B-prolymphocytes are medium-sized, round lymphoid cells with prominent nucleoli.  The B-prolymphocytes must exceed 55% of lymphoid cells in the blood.  Cases of transformed chronic lymphocytic leukemia (CLL) and CLL with increased prolymphocytes are excluded.  The prognosis is poor.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-47FB-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6281C75A-4814-A127-E040-BB89AD431A41","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Atypical Chronic Myeloid Leukemia","valueDescription":"Atypical Chronic Myeloid Leukemia","ValueMeaning":{"publicId":"2837831","version":"1","preferredName":"Atypical Chronic Myeloid Leukemia","longName":"2837831","preferredDefinition":"A myelodysplastic/myeloproliferative disease characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia.  The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Chronic Myeloid Leukemia","conceptCode":"C3519","definition":"A myelodysplastic/myeloproliferative neoplasm characterized by the presence of leukocytosis with increased numbers of neutrophils, promyelocytes, myelocytes, and metamyelocytes; blasts less than 20% in bone marrow and peripheral blood; dysgranulopoiesis; minimal or absent monocytosis; absence of eosinophilia; and presence of bone marrow hypercellularity with granulocytic proliferation and granulocytic dysplasia. Dysplasia in the erythroid and megakaryocytic lineages may be present or absent. No evidence of BCR/ABL fusion is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-481E-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6281C75A-4837-A127-E040-BB89AD431A41","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Carcinoma With Cartilaginous Or Osseous Metaplasia","valueDescription":"Adenocarcinoma with Cartilaginous and Osseous Metaplasia","ValueMeaning":{"publicId":"2837834","version":"1","preferredName":"Adenocarcinoma with Cartilaginous and Osseous Metaplasia","longName":"2837834","preferredDefinition":"An invasive adenocarcinoma characterized by focal or extensive cartilage and/or bone formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma with Cartilaginous and Osseous Metaplasia","conceptCode":"C7683","definition":"An invasive adenocarcinoma characterized by focal or extensive cartilage and/or bone formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-4868-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6281C75A-4881-A127-E040-BB89AD431A41","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Carcinoma - Non small cell type","valueDescription":"Non-Small Cell Carcinoma","ValueMeaning":{"publicId":"2837836","version":"1","preferredName":"Non-Small Cell Carcinoma","longName":"2837836","preferredDefinition":"A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Small Cell Carcinoma","conceptCode":"C65151","definition":"A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-488E-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6281C75A-48A7-A127-E040-BB89AD431A41","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Cannot be determined","valueDescription":"Indeterminate","ValueMeaning":{"publicId":"2577194","version":"1","preferredName":"Indeterminate","longName":"2577194","preferredDefinition":"Cannot distinguish between two or more possible values in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate","conceptCode":"C48658","definition":"Cannot distinguish between two or more possible values in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA97-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"COOPERM","dateModified":"2008-09-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6281C75A-48B1-A127-E040-BB89AD431A41","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Choriocarcinoma","valueDescription":"Choriocarcinoma","ValueMeaning":{"publicId":"2837860","version":"1","preferredName":"Choriocarcinoma","longName":"2837860","preferredDefinition":"An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choriocarcinoma","conceptCode":"C2948","definition":"An aggressive malignant tumor arising from trophoblastic cells. The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells. Approximately half of the cases develop from a complete hydatidiform mole. A minority of cases arise in the testis or the ovaries. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-491B-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6281C75A-4934-A127-E040-BB89AD431A41","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Carcinoma With Squamous Metaplasia","valueDescription":"Adenocarcinoma with Squamous Metaplasia","ValueMeaning":{"publicId":"2837862","version":"1","preferredName":"Adenocarcinoma with Squamous Metaplasia","longName":"2837862","preferredDefinition":"An invasive adenocarcinoma characterized by the presence of focal or extensive transformation of malignant glandular cells to squamous epithelial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma with Squamous Metaplasia","conceptCode":"C4200","definition":"An invasive adenocarcinoma characterized by the presence of focal or extensive transformation of malignant glandular cells to squamous epithelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-4941-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6281C75A-495A-A127-E040-BB89AD431A41","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Carcinoma With Spindle Cell Metaplasia","valueDescription":"Adenocarcinoma with Spindle Cell Metaplasia","ValueMeaning":{"publicId":"2837864","version":"1","preferredName":"Adenocarcinoma with Spindle Cell Metaplasia","longName":"2837864","preferredDefinition":"An invasive adenocarcinoma characterized by focal or extensive transformation of the malignant glandular cells to spindle-shaped cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma with Spindle Cell Metaplasia","conceptCode":"C4201","definition":"An invasive adenocarcinoma characterized by focal or extensive transformation of the malignant glandular cells to spindle-shaped cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-4967-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6281C75A-4980-A127-E040-BB89AD431A41","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Chronic Idiopathic Myelofibrosis","valueDescription":"Chronic Idiopathic Myelofibrosis","ValueMeaning":{"publicId":"2837867","version":"1","preferredName":"Chronic Idiopathic Myelofibrosis","longName":"2837867","preferredDefinition":"A chronic myeloproliferative disorder characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes (micromegakaryocytes) and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis.  The cause is unknown.  The median survival time is 3-5 years from diagnosis. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Myelofibrosis","conceptCode":"C2862","definition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-49B6-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6281C75A-49CF-A127-E040-BB89AD431A41","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Choroid Plexus Papilloma","valueDescription":"Choroid Plexus Papilloma","ValueMeaning":{"publicId":"2572938","version":"1","preferredName":"Choroid Plexus Papilloma","longName":"2572938","preferredDefinition":"Choroid Plexus Papilloma (WHO grade I) is a benign, slow growing tumor which may cause symptoms by blocking CSF pathways. Surgical resection is usually curative. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choroid Plexus Papilloma","conceptCode":"C3698","definition":"A benign, slow growing tumor which may cause symptoms by blocking cerebrospinal fluid pathways.  It is characterized by the presence of delicate fibrovascular connective tissue fronds covered by a single layer of epithelial cells.  Mitotic activity is extremely low.  Surgical resection is usually curative. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9F7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6281C75A-49D9-A127-E040-BB89AD431A41","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Choroid Plexus Carcinoma","valueDescription":"Choroid plexus carcinoma","ValueMeaning":{"publicId":"2578711","version":"1","preferredName":"Choroid plexus carcinoma","longName":"2578711","preferredDefinition":"Choroid Plexus Carcinoma (WHO grade III) is a malignant Choroid Plexus Tumor which shows anaplastic features and usually invades neighboring brain structures. CSF metastases are frequent. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choroid Plexus Carcinoma","conceptCode":"C4715","definition":"A malignant neoplasm arising from the choroid plexus.  It shows anaplastic features and usually invades neighboring brain structures. Cerebrospinal fluid metastases are frequent. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0084-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6281C75A-49E4-A127-E040-BB89AD431A41","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Follicular Lymphoma Grade 1","valueDescription":"Grade 1 Follicular Lymphoma","ValueMeaning":{"publicId":"2593080","version":"1","preferredName":"Grade 1 Follicular Lymphoma","longName":"2593080","preferredDefinition":"A low-grade malignant lymphoma of predominantly follicular pattern. Follicles are of relatively uniform size and shape and the cells are usually somewhat larger than normal lymphocytes. Nuclei are irregular with prominent indentations and cytoplasm can rarely be identified. Cells exhibiting these characteristics are often called small cleaved cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 1 Follicular Lymphoma","conceptCode":"C3465","definition":"A follicular lymphoma which contains up to 5 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A3B-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6332FCA8-8A67-1FC8-E040-BB89AD432A49","beginDate":"2009-02-18","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-18","modifiedBy":"ONEDATA","dateModified":"2009-02-18","deletedIndicator":"No"},{"value":"Follicular Lymphoma Grade 2","valueDescription":"Grade 2 Follicular Lymphoma","ValueMeaning":{"publicId":"2593082","version":"1","preferredName":"Grade 2 Follicular Lymphoma","longName":"2593082v1.00","preferredDefinition":"A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 2 Follicular Lymphoma","conceptCode":"C8968","definition":"A follicular lymphoma which contains 6-15 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A62-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6332FCA8-8A52-1FC8-E040-BB89AD432A49","beginDate":"2009-02-18","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-18","modifiedBy":"ONEDATA","dateModified":"2009-02-18","deletedIndicator":"No"},{"value":"Follicular Dendritic Cell Sarcoma or Tumor","valueDescription":"Follicular Dendritic Cell Sarcoma/Tumor","ValueMeaning":{"publicId":"2839726","version":"1","preferredName":"Follicular Dendritic Cell Sarcoma/Tumor","longName":"2839726","preferredDefinition":"A neoplasm composed of spindle to ovoid cells which have morphologic and immunophenotypic characteristics of follicular dendritic cells. It affects lymph nodes and other sites including the tonsils, gastrointestinal tract, spleen, liver, soft tissues, skin, and oral cavity. It usually behaves as a low grade sarcoma. Treatment options include complete surgical removal of the tumor with or without adjuvant chemotherapy or radiotherapy. Recurrences have been reported in up to half of the cases. Cases which present with abdominal involvement and a high morphologic grade usually have a poorer prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Dendritic Cell Sarcoma","conceptCode":"C9281","definition":"A neoplasm composed of spindle to ovoid cells which have morphologic and immunophenotypic characteristics of follicular dendritic cells. It affects lymph nodes and other sites including the tonsils, gastrointestinal tract, spleen, liver, soft tissues, skin, and oral cavity. It usually behaves as a low grade sarcoma. Treatment options include complete surgical removal of the tumor with or without adjuvant chemotherapy or radiotherapy. Recurrences have been reported in up to half of the cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6332FCA8-8A75-1FC8-E040-BB89AD432A49","latestVersionIndicator":"Yes","beginDate":"2009-02-18","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-18","modifiedBy":"ONEDATA","dateModified":"2009-02-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6332FCA8-8A8E-1FC8-E040-BB89AD432A49","beginDate":"2009-02-18","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-18","modifiedBy":"ONEDATA","dateModified":"2009-02-18","deletedIndicator":"No"},{"value":"Follicular Lymphoma Grade 3","valueDescription":"Grade 3 Follicular Lymphoma","ValueMeaning":{"publicId":"2593084","version":"1","preferredName":"Grade 3 Follicular Lymphoma","longName":"2593084","preferredDefinition":"A follicular lymphoma which contains more than 15 centroblasts per 40X high-power microscopic field.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3 Follicular Lymphoma","conceptCode":"C3460","definition":"A follicular lymphoma which contains more than 15 centroblasts per 40X high-power microscopic field.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1A89-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6332FCA8-8AA3-1FC8-E040-BB89AD432A49","beginDate":"2009-02-18","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-18","modifiedBy":"ONEDATA","dateModified":"2009-02-18","deletedIndicator":"No"},{"value":"Signet Ring Cell Carcinoma","valueDescription":"Signet Ring Cell Carcinoma","ValueMeaning":{"publicId":"2838829","version":"1","preferredName":"Signet Ring Cell Carcinoma","longName":"2838829","preferredDefinition":"A highly malignant type of cancer typically found in glandular cells that line the digestive organs. The cells resemble signet rings when examined under a microscope.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Signet Ring Cell Carcinoma","conceptCode":"C3774","definition":"A usually aggressive, poorly differentiated invasive adenocarcinoma characterized by the presence of malignant glandular cells in which the nucleus is pressed to one side by the presence of intracytoplasmic mucus. It may arise from the stomach, small and large intestine, ampulla of Vater, appendix, gallbladder, pancreas, lung, bladder, breast, and prostate gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A92F7C-99F3-B744-E040-BB89AD434761","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A92F7C-9A0C-B744-E040-BB89AD434761","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Serous Cystadenocarcinoma","valueDescription":"Serous Cystadenocarcinoma","ValueMeaning":{"publicId":"2581792","version":"1","preferredName":"Serous Cystadenocarcinoma","longName":"2581792","preferredDefinition":"A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Serous Cystadenocarcinoma","conceptCode":"C3778","definition":"A malignant serous cystic neoplasm usually involving the ovary or the pancreas. It is characterized by the presence of invasive malignant glandular epithelial cells which often form papillary structures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C8D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A92F7C-9A16-B744-E040-BB89AD434761","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Schwannoma - Plexiform","valueDescription":"Plexiform Schwannoma","ValueMeaning":{"publicId":"2838831","version":"1","preferredName":"Plexiform Schwannoma","longName":"2838831","preferredDefinition":"Plexiform Schwannoma (also called Plexiform Neurilemmoma and Plexiform Neurinoma) is a Schwannoma which grows in a plexiform or multinodular manner, presumably involving a nerve plexus. The majority arise in skin or subcutaneous tissue of an extremity, head and neck or trunk. The tumor is associated with Neurofibromatosis Type 1. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plexiform Schwannoma","conceptCode":"C6969","definition":"A schwannoma characterized by a plexiform or multinodular growth pattern.  It usually arises from the skin or subcutaneous tissues in the extremities, trunk, and head and neck.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A92F7C-9A24-B744-E040-BB89AD434761","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A92F7C-9A3D-B744-E040-BB89AD434761","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Schwannoma - Not Otherwise Characterized","valueDescription":"Schwannoma","ValueMeaning":{"publicId":"2575032","version":"1","preferredName":"Schwannoma","longName":"2575032","preferredDefinition":"A tumor of the peripheral nervous system that arises in the nerve sheath (protective covering).  It is almost always benign, but rare malignant schwannomas have been reported.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Schwannoma","conceptCode":"C3269","definition":"A benign, usually encapsulated slow growing tumor composed of Schwann cells.  It affects peripheral and cranial nerves.  It recurs infrequently and only rare cases associated with malignant transformation have been reported.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F225-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-05-23","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A92F7C-9A51-B744-E040-BB89AD434761","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Langerhans Cell Sarcoma","valueDescription":"Langerhans Cell Sarcoma","ValueMeaning":{"publicId":"2838587","version":"1","preferredName":"Langerhans Cell Sarcoma","longName":"2838587","preferredDefinition":"A neoplastic proliferation of Langerhans cells with overtly malignant cytologic features.  It can be considered a higher grade variant of Langerhans cell histiocytosis (LCH) and it can present de novo or progress from antecedent LCH. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Langerhans Cell Sarcoma","conceptCode":"C6921","definition":"A neoplastic proliferation of Langerhans cells with overtly malignant cytologic features.  It can be considered a higher grade variant of Langerhans cell histiocytosis (LCH) and it can present de novo or progress from antecedent LCH. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F6B4-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A5F1C9-F6CD-B082-E040-BB89AD436154","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Langerhans Cell Histiocytosis","valueDescription":"Langerhans Cell Histiocytosis","ValueMeaning":{"publicId":"2838588","version":"1","preferredName":"Langerhans Cell Histiocytosis","longName":"2838588","preferredDefinition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Langerhans Cell Histiocytosis","conceptCode":"C3107","definition":"A neoplastic proliferation of Langerhans cells which contain Birbeck granules by ultrastructural examination. Three major overlapping syndromes are recognized: eosinophilic granuloma, Letterer-Siwe disease, and Hand-Schuller-Christian disease. The clinical course is generally related to the number of organs affected at presentation. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F6D7-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A5F1C9-F6F0-B082-E040-BB89AD436154","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Lymphocyte-Rich Classical Hodgkin Lymphoma","valueDescription":"Lymphocyte Rich Classical Hodgkin Lymphoma","ValueMeaning":{"publicId":"2593110","version":"1","preferredName":"Lymphocyte Rich Classical Hodgkin Lymphoma","longName":"2593110","preferredDefinition":"A subtype of classical Hodgkin lymphoma.  Most patients present with peripheral lymphadenopathy and limited stage disease (stage I or II).  The survival and progression free survival are slightly better than in other subtypes of classical Hodgkin lymphoma. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocyte-Rich Classic Hodgkin Lymphoma","conceptCode":"C6913","definition":"A subtype of classic Hodgkin lymphoma with scattered Hodgkin and Reed-Sternberg cells and a nodular or less often diffuse cellular background consisting of small lymphocytes and with an absence of neutrophils and eosinophils. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D2655-C748-1ADB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A5F1C9-F752-B082-E040-BB89AD436154","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Lymphocyte-Depleted Classical Hodgkin Lymphoma","valueDescription":"Lymphocyte Depleted Hodgkin Lymphoma","ValueMeaning":{"publicId":"2593114","version":"1","preferredName":"Lymphocyte Depleted Hodgkin Lymphoma","longName":"2593114","preferredDefinition":"A diffuse form of classical Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes.  Historically, the clinical course of this type of Hodgkin lymphoma was aggressive.  With current therapy, the course is comparable to patients with other subtypes of classical Hodgkin lymphoma.  Most patients present with advanced stage disease (Stage III or IV) and B-symptoms. (WHO, 2001) -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphocyte-Depleted Classic Hodgkin Lymphoma","conceptCode":"C9283","definition":"A diffuse subtype of classic Hodgkin lymphoma which is rich in Hodgkin and Reed-Sternberg cells and/or depleted in non-neoplastic lymphocytes. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D2655-C796-1ADB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A5F1C9-F767-B082-E040-BB89AD436154","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Lobular Carcinoma In Situ","valueDescription":"Lobular Breast Carcinoma In Situ","ValueMeaning":{"publicId":"2581227","version":"1","preferredName":"Lobular Breast Carcinoma In Situ","longName":"2581227","preferredDefinition":"Lobular carcinoma in situ is characterized by a proliferation of monomorphic cells completely filling the lumina. The overall lobular architecture is preserved. LCIS is frequently multifocal (90% in some series) and bilateral. LCIS seldom becomes invasive, however there is an increased risk of infiltrating ductal adenocarcinoma.  --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Lobular Carcinoma In Situ","conceptCode":"C4018","definition":"A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina.  The overall lobular architecture is preserved.  It is frequently multifocal (90% in some series) and bilateral.  It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A58-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A5F1C9-F77C-B082-E040-BB89AD436154","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Lentigo Maligna Melanoma","valueDescription":"Lentigo Maligna Melanoma","ValueMeaning":{"publicId":"2569595","version":"1","preferredName":"Lentigo Maligna Melanoma","longName":"2569595","preferredDefinition":"(A melanoma of the skin characterized by single cell infiltration of the papillary dermis by atypical melanocytes, in a background of lentigo maligna changes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lentigo Maligna Melanoma","conceptCode":"C9151","definition":"A melanoma of the skin characterized by single cell infiltration of the papillary dermis by atypical melanocytes, in a background of lentigo maligna changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DCE8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-09","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2004-05-13","modifiedBy":"DWARZEL","dateModified":"2006-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A5F1C9-F786-B082-E040-BB89AD436154","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Large Cell Neuroendocrine Carcinoma","valueDescription":"Large Cell Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"2838592","version":"1","preferredName":"Large Cell Neuroendocrine Carcinoma","longName":"2838592","preferredDefinition":"A usually aggressive carcinoma composed of large malignant cells which display neuroendocrine characteristics. It is characterized by the presence of high mitotic activity and necrotic changes. The vast majority of cases are positive for neuron-specific enolase. Representative examples include lung, breast, cervical, and thymic neuroendocrine carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Large Cell Neuroendocrine Carcinoma","conceptCode":"C6875","definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation. It is composed of malignant large cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F794-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2018-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A5F1C9-F7AD-B082-E040-BB89AD436154","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Malignant Blue Nevus","valueDescription":"Blue Nevus-Like Melanoma","ValueMeaning":{"publicId":"2569599","version":"1","preferredName":"Blue Nevus-Like Melanoma","longName":"2569599","preferredDefinition":"A melanoma of the skin resembling a benign blue nevus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma Arising from Blue Nevus","conceptCode":"C4240","definition":"A rare melanoma which develops in a pre-existing blue nevus. It occurs more frequently on the scalp, face, orbit, back, buttocks, extremities, hands, and feet.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DCEC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2004-05-13","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A5F1C9-F7B8-B082-E040-BB89AD436154","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Lymphoplasmacytic Lymphoma","valueDescription":"Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia","ValueMeaning":{"publicId":"2593073","version":"1","preferredName":"Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia","longName":"2593073","preferredDefinition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen.  The majority of patients have a serum IgM paraprotein.  Lymphoplasmacytic lymphoma/ Waldenstrom's Macroglobulinemia is a relatively rare condition accounting for approximately 2% of hematologic malignancies.  Symptoms include: weakness and fatigue, hemorrhagic manifestations, weight loss and visual disturbances.  Physical findings include: hepatomegaly, splenomegaly, fundic changes, adenopathy, neurologic abnormalities and purpura.  The most common laboratory finding is anemia.  Treatment includes: chemotherapy (alkylating agents, nucleoside analogues) radiotherapy and plasmapheresis.  Bone marrow transplant is being investigated.  Asymptomatic patients may be monitored without treatment until complications occur. - 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoplasmacytic Lymphoma","conceptCode":"C3212","definition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-1974-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A5F1C9-F7C3-B082-E040-BB89AD436154","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Lymphomatoid Papulosis","valueDescription":"Lymphomatoid Papulosis","ValueMeaning":{"publicId":"2838593","version":"1","preferredName":"Lymphomatoid Papulosis","longName":"2838593","preferredDefinition":"This is a chronic, recurrent skin disease characterized by spontaneously regressing papules composed of an atypical CD30-positive T-cell population.  The disease is defined as an atypical lymphoproliferative process and usually has a benign course.  However, a minority of cases are clonal and can progress to frank lymphoma.  Low dose methotrexate and psoralen/UVA (PUVA) are the best available therapies.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphomatoid Papulosis","conceptCode":"C3721","definition":"A chronic, recurrent cutaneous disorder characterized by the presence of spontaneously regressing papules.  The papules are composed of an atypical lymphocytic infiltrate that contains anaplastic CD30-positive T-cells, which are found in type A and diffuse large cell type (type C) lymphomatoid papulosis.  In a small number of cases, of type B, the lymphocytic infiltrate is composed of small, cerebriform-like lymphocytes that are often negative for CD30.  The majority of cases follow a benign clinical course, but some cases are clonal and may progress to lymphoma.  Treatment options include low dose methotrexate and psoralen/UVA (PUVA).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F7CE-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A5F1C9-F7E7-B082-E040-BB89AD436154","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Lymphomatoid Granulomatosis","valueDescription":"Lymphomatoid Granulomatosis","ValueMeaning":{"publicId":"2838594","version":"1","preferredName":"Lymphomatoid Granulomatosis","longName":"2838594","preferredDefinition":"An angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites, comprised of Epstein-Barr virus (EBV)-positive B-cells admixed with reactive T-cells.  Incidence is higher among adult males; patients with a history of immunodeficiency are at increased risk.  The most common site of involvement is the lung; other common sites include brain, kidney, liver, and skin.  Morphologically, three grades are recognized: grade I, II, and III.  Grade III lymphomatoid granulomatosis should be approached clinically as a subtype of diffuse large B-cell lymphoma. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphomatoid Granulomatosis","conceptCode":"C7930","definition":"An angiocentric and angiodestructive lymphoproliferative disease involving extranodal sites, comprised of Epstein-Barr virus (EBV)-positive B-cells admixed with reactive T-cells.  Incidence is higher among adult males; patients with a history of immunodeficiency are at increased risk.  The most common site of involvement is the lung; other common sites include brain, kidney, liver, and skin.  Morphologically, three grades are recognized: grade I, II, and III.  Grade III lymphomatoid granulomatosis should be approached clinically as a subtype of diffuse large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F7F1-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A5F1C9-F80A-B082-E040-BB89AD436154","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia - Without Maturation","valueDescription":"Acute Myeloid Leukemia without Maturation","ValueMeaning":{"publicId":"2836808","version":"1","preferredName":"Acute Myeloid Leukemia without Maturation","longName":"2836808","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia without Maturation","conceptCode":"C3249","definition":"An acute myeloid leukemia (AML) characterized by blasts without evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246BA48-A96F-2000-E040-BB89AD437D62","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6246BA48-A988-2000-E040-BB89AD437D62","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia - With Maturation","valueDescription":"Acute Myeloid Leukemia with Maturation","ValueMeaning":{"publicId":"2836809","version":"1","preferredName":"Acute Myeloid Leukemia with Maturation","longName":"2836809","preferredDefinition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Maturation","conceptCode":"C3250","definition":"An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6246BA48-A992-2000-E040-BB89AD437D62","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"HARTLEYG","dateModified":"2016-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6246BA48-A9AB-2000-E040-BB89AD437D62","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Chronic Myelomonocytic Leukemia","valueDescription":"Chronic Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2771865","version":"1","preferredName":"Chronic Myelomonocytic Leukemia","longName":"2771865","preferredDefinition":"A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myelomonocytic Leukemia","conceptCode":"C3178","definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54342348-5E2F-4602-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SOKKERL","dateModified":"2022-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6282862D-CE46-EC8D-E040-BB89AD434A77","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Chronic Myelogenous Leukemia","valueDescription":"CML","ValueMeaning":{"publicId":"2837953","version":"1","preferredName":"CML","longName":"2837953","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6282862D-CE51-EC8D-E040-BB89AD434A77","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6282862D-CE6A-EC8D-E040-BB89AD434A77","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma","valueDescription":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","ValueMeaning":{"publicId":"2837954","version":"1","preferredName":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","longName":"2837954","preferredDefinition":"An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","conceptCode":"C27911","definition":"An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6282862D-CE74-EC8D-E040-BB89AD434A77","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6282862D-CE8D-EC8D-E040-BB89AD434A77","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Chronic Neutrophilic Leukemia","valueDescription":"Chronic Neutrophilic Leukemia","ValueMeaning":{"publicId":"2837958","version":"1","preferredName":"Chronic Neutrophilic Leukemia","longName":"2837958","preferredDefinition":"A rare chronic myeloproliferative disorder characterised by neutrophilic leukocytosis.  There is no detectable Philadelphia chromosome or BCR/ABL fusion gene.  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Neutrophilic Leukemia","conceptCode":"C3179","definition":"A rare chronic myeloproliferative neoplasm characterized by neutrophilic leukocytosis.  There is no detectable Philadelphia chromosome or BCR/ABL fusion gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6282862D-CECC-EC8D-E040-BB89AD434A77","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6282862D-CEE5-EC8D-E040-BB89AD434A77","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","deletedIndicator":"No"},{"value":"Nodular Sclerosis Classical Hodgkin Lymphoma","valueDescription":"Nodular Sclerosis Hodgkin Lymphoma","ValueMeaning":{"publicId":"2593112","version":"1","preferredName":"Nodular Sclerosis Hodgkin Lymphoma","longName":"2593112","preferredDefinition":"A subtype of classical Hodgkin lymphoma characterized by collagen bands surrounding lymphoid nodules. The lymphoid nodules contain lacunar and Reed-Sternberg cells.  Mediastinal involvement occurs in 80% of patients.  The prognosis of nodular sclerosis Hodgkin lymphoma is slightly better than that of mixed cellularity or lymphocyte depleted subtype. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Sclerosis Classic Hodgkin Lymphoma","conceptCode":"C3518","definition":"A subtype of classic Hodgkin lymphoma characterized by collagen bands that surround at least one nodule, and Hodgkin and Reed-Sternberg cells with lacunar type morphology. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D2655-C76F-1ADB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-956B-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Nodular Melanoma","valueDescription":"Nodular Melanoma","ValueMeaning":{"publicId":"2569596","version":"1","preferredName":"Nodular Melanoma","longName":"2569596","preferredDefinition":"An aggressive form of melanoma, frequently metastasizing to the lymph nodes. It presents as a papular or nodular raised skin lesion. It comprises approximately 10-15% of melanomas. Morphologically, it often displays an epithelioid appearance.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutaneous Nodular Melanoma","conceptCode":"C4225","definition":"An aggressive form of melanoma, frequently metastasizing to the lymph nodes.  It presents as a papular or nodular raised skin lesion.  It comprises approximately 10-15% of melanomas.  Morphologically, it often displays an epithelioid appearance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DCE9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2004-05-13","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-9576-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Nodular Lymphocyte Predominant Hodgkin Lymphoma","valueDescription":"Nodular Lymphocyte Predominant Hodgkin Lymphoma","ValueMeaning":{"publicId":"2838645","version":"1","preferredName":"Nodular Lymphocyte Predominant Hodgkin Lymphoma","longName":"2838645","preferredDefinition":"A monoclonal B-cell neoplasm characterized by a nodular, or a nodular and diffuse, polymorphous proliferation of scattered large neoplastic cells known as popcorn or L&H cells; the L&H cells are CD15 negative, and rarely positive for CD30 antigen.  Patients are predominantly male, frequently in the 30-50 year age group.  Most patients present with limited stage disease (localized peripheral lymphadenopathy, stage I or II); the prognosis of patients with stage I and stage II disease is very good.  Advanced stages have an unfavorable prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Lymphocyte Predominant B-Cell Lymphoma","conceptCode":"C7258","definition":"A B-cell lymphoma characterized by the presence of scattered clonal cells known as lymphocyte predominant cells (LP cells) in a background of reactive lymphocytes and histiocytes, and formation of a nodular or nodular and diffuse growth pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-9584-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"DWARZEL","dateModified":"2012-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-959D-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Oligoastrocytoma - Anaplastic","valueDescription":"Anaplastic oligoastrocytoma","ValueMeaning":{"publicId":"2568646","version":"1","preferredName":"Anaplastic oligoastrocytoma","longName":"2568646","preferredDefinition":"Anaplastic Oligoastrocytoma is an Oligoastrocytoma with histological features of malignancy, such as increased cellularity, nuclear atypia, pleomorphism, and increased mitotic activity. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Oligoastrocytoma","conceptCode":"C6959","definition":"An oligoastrocytoma characterized by the presence of increased cellularity, nuclear atypia, pleomorphism, and high mitotic activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D933-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-10","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2004-03-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-95B2-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Not Specified","valueDescription":"Unspecified","ValueMeaning":{"publicId":"2573360","version":"1","preferredName":"Unspecified","longName":"2573360","preferredDefinition":"Not stated explicitly or in detail.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unspecified","conceptCode":"C38046","definition":"Not stated explicitly or in detail.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EB9D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-03-06","modifiedBy":"TSESU","dateModified":"2023-06-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-95BD-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-95C7-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Oligodendroglioma - Anaplastic","valueDescription":"Anaplastic oligodendroglioma","ValueMeaning":{"publicId":"2572933","version":"1","preferredName":"Anaplastic oligodendroglioma","longName":"2572933","preferredDefinition":"A WHO grade III oligodendroglioma with focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Oligodendroglioma","conceptCode":"C4326","definition":"A WHO grade 3 oligodendroglioma with focal or diffuse malignant morphologic features (prominent nuclear pleomorphism, mitoses, and increased cellularity).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9F2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-95DC-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Oligoastrocytoma - Not Otherwise Characterized","valueDescription":"Oligoastrocytoma","ValueMeaning":{"publicId":"2838647","version":"1","preferredName":"Oligoastrocytoma","longName":"2838647","preferredDefinition":"A WHO grade II tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligoastrocytoma","conceptCode":"C4050","definition":"A WHO grade 2 tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-95EA-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-9603-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Polycythemia Vera","valueDescription":"Polycythemia Vera","ValueMeaning":{"publicId":"2838666","version":"1","preferredName":"Polycythemia Vera","longName":"2838666","preferredDefinition":"A chronic myeloproliferative disorder characterized by an increased red blood cell production.  Excessive proliferation of the myeloid lineage is observed as well.  The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass.  The cause is unknown.  With currently available treatment, the median survival exceeds 10 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polycythemia Vera","conceptCode":"C3336","definition":"A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. The bone marrow is hypercellular due to a panmyelotic proliferation typically characterized by pleomorphic megakaryocytes. The major symptoms are related to hypertension, splenomegaly or to episodes of thrombosis and/or hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-960E-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-9627-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Plasma Cell Myeloma","valueDescription":"Myeloma","ValueMeaning":{"publicId":"2838667","version":"1","preferredName":"Myeloma","longName":"2838667","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-9631-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-964A-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Precursor B Lymphoblastic Leukemia Or Lymphoblastic Lymphoma","valueDescription":"Precursor B-Lymphoblastic Lymphoma/Leukemia","ValueMeaning":{"publicId":"2593075","version":"1","preferredName":"Precursor B-Lymphoblastic Lymphoma/Leukemia","longName":"2593075","preferredDefinition":"A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called precursor B lymphoblastic leukemia (B-cell acute lymphoblastic leukemia).  When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Lymphoblastic Leukemia/Lymphoma","conceptCode":"C8936","definition":"A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called B acute lymphoblastic leukemia.  When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286C5855-19BC-6248-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-965F-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Post Transplant Lymphoproliferative Disorder - Polymorphic","valueDescription":"Polymorphic Post-Transplant Lymphoproliferative Disorder","ValueMeaning":{"publicId":"2838669","version":"1","preferredName":"Polymorphic Post-Transplant Lymphoproliferative Disorder","longName":"2838669v1.00","preferredDefinition":"A clonal B-cell lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a polymorphic B-cell infiltrate composed of small and medium sized lymphocytes, immunoblasts, and plasma cells. In some cases, reduction of the immunosuppression therapy may lead to regression of the lesions. In other cases the lesions may progress to lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polymorphic Post-Transplant Lymphoproliferative Disorder","conceptCode":"C7183","definition":"A clonal B-cell lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a polymorphic B-cell infiltrate composed of small and medium sized lymphocytes, immunoblasts, and plasma cells. In some cases, reduction of the immunosuppression therapy may lead to regression of the lesions. In other cases the lesions may progress to lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-966D-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-9686-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Primary Amyloidosis","valueDescription":"Primary Amyloidosis","ValueMeaning":{"publicId":"2838692","version":"1","preferredName":"Primary Amyloidosis","longName":"2838692","preferredDefinition":"A plasma cell neoplasm that secretes an abnormal immunoglobulin, which deposits in various tissues and forms a beta-pleated sheet structure that binds Congo red dye with characteristic birefringence.  The sites of involvement include heart, liver, kidney, gut, tongue, nerves, and bone. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Amyloidosis","conceptCode":"C3819","definition":"A plasma cell neoplasm that secretes an abnormal immunoglobulin, which deposits in tissues and forms a beta-pleated sheet structure that binds Congo red dye with characteristic birefringence. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-96E1-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-96FA-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Precursor T Lymphoblastic Leukemia Or Lymphoblastic Lymphoma","valueDescription":"precursor T-lymphoblastic lymphoma/leukemia","ValueMeaning":{"publicId":"2568286","version":"1","preferredName":"Precursor T-lymphoblastic lymphoma/leukemia","longName":"2568286v1.00","preferredDefinition":"A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Lymphoblastic Leukemia/Lymphoma","conceptCode":"C8694","definition":"A neoplasm of lymphoblasts committed to the T-cell lineage, typically composed of small to medium-sized blast cells.  When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called T acute lymphoblastic leukemia.  When it involves nodal or extranodal sites it is called T lymphoblastic lymphoma. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7CB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-30","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-970E-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Primary Cutaneous Anaplastic Large Cell Lymphoma","valueDescription":"Primary Cutaneous Anaplastic Large Cell Lymphoma","ValueMeaning":{"publicId":"2838708","version":"1","preferredName":"Primary Cutaneous Anaplastic Large Cell Lymphoma","longName":"2838708","preferredDefinition":"An anaplastic large cell lymphoma limited to the skin at the time of diagnosis.  Most patients present with solitary or localized skin lesions, which may be tumors, nodules or papules.  The t(2;5) translocation that is present in many cases of systemic anaplastic large cell lymphoma, is not found in this disease. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Cutaneous Anaplastic Large Cell Lymphoma","conceptCode":"C6860","definition":"An anaplastic large cell lymphoma limited to the skin at the time of diagnosis.  Most patients present with solitary or localized skin lesions, which may be tumors, nodules or papules.  The t(2;5) translocation that is present in many cases of systemic anaplastic large cell lymphoma, is not found in this disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-971A-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-9733-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Refractory Anemia With Excess Blasts (RAEB) - 1","valueDescription":"RAEB-1","ValueMeaning":{"publicId":"2582031","version":"1","preferredName":"RAEB-1","longName":"2582031","preferredDefinition":"A myelodysplastic syndrome defined by 5-9% blasts in the bone marrow, and <5% blasts in the blood.  Approximately 25% of cases progress to an acute leukemia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Excess Blasts-1","conceptCode":"C7167","definition":"A myelodysplastic syndrome defined by 5-9% blasts in the bone marrow, and <5% blasts in the blood.  Approximately 25% of cases progress to an acute leukemia. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0D7C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":"Fixed the less than symbol in System Generated Value Meaning Description by removing and replacing the associated concept. dbw Dec-20-2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-9748-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Refractory Anemia With Excess Blasts (RAEB)","valueDescription":"Refractory Anemia with Excess Blasts","ValueMeaning":{"publicId":"2838712","version":"1","preferredName":"Myelodysplastic Syndrome with Excess Blasts","longName":"2838712v1.00","preferredDefinition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Excess Blasts","conceptCode":"C7506","definition":"Myelodysplastic syndrome characterized by the presence of 5-9% blasts in bone marrow and 2-9% blasts in peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-9753-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-976C-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Refractory Anemia","valueDescription":"Refractory Anemia","ValueMeaning":{"publicId":"2771856","version":"1","preferredName":"Refractory Anemia","longName":"2771856","preferredDefinition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Refractory Anemia","conceptCode":"C2872","definition":"A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series.  Refractory anemia is uncommon.  It is primarily a disease of older adults.  The median survival exceeds 5 years.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF1D-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A740CA-9776-2FE1-E040-BB89AD4311CA","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia and Myelodysplastic Syndromes - Alkylating Agent Related","valueDescription":"Alkylating Agent-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome","ValueMeaning":{"publicId":"2836814","version":"1","preferredName":"Alkylating Agent-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome","longName":"2836814v1.00","preferredDefinition":"Acute myeloid leukemias and myelodysplastic syndromes arising as a result of the mutagenic effect of alkylating agents that are used for the treatment of malignant tumors. Patients usually develop a myelodysplastic syndrome which may evolve to a higher grade myelodysplastic syndrome or acute myeloid leukemia. A minority of patients present with an acute myeloid leukemia. Clonal cytogenetic abnormalities are frequently present and usually are unbalanced translocations or deletions of chromosomes 5 and 7. Patients with acute myeloid leukemia usually do not respond to treatment and have an unfavorable clinical outcome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alkylating Agent-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome","conceptCode":"C27913","definition":"Acute myeloid leukemias and myelodysplastic syndromes arising as a result of the mutagenic effect of alkylating agents that are used for the treatment of malignant tumors. Patients usually develop a myelodysplastic syndrome which may evolve to a higher grade myelodysplastic syndrome or acute myeloid leukemia. A minority of patients present with an acute myeloid leukemia. Clonal cytogenetic abnormalities are frequently present and usually are unbalanced translocations or deletions of chromosomes 5 and 7. Patients with acute myeloid leukemia usually do not respond to treatment and have an unfavorable clinical outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-05F1-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-060A-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia and Myelodysplastic Syndromes - Topoisomerase Type II Inhibitor Related","valueDescription":"Topoisomerase II Inhibitor-Related Acute Myeloid Leukemia","ValueMeaning":{"publicId":"2836810","version":"1","preferredName":"Topoisomerase II Inhibitor-Related Acute Myeloid Leukemia","longName":"2836810v1.00","preferredDefinition":"Acute myeloid leukemias arising as a result of the mutagenic effect of therapeutic agents targeting DNA-topoisomerase II. The vast majority of patients present without a preceding myelodysplastic phase. The acute myeloid leukemias are usually of the monoblastic or myelomonocytic type. Clonal cytogenetic abnormalities are frequently present and usually involve chromosome 11q23 (MLL gene).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topoisomerase II Inhibitor-Related Acute Myeloid Leukemia","conceptCode":"C27755","definition":"Acute myeloid leukemias arising as a result of the mutagenic effect of therapeutic agents targeting DNA-topoisomerase II. The vast majority of patients present without a preceding myelodysplastic phase. The acute myeloid leukemias are usually of the monoblastic or myelomonocytic type. Clonal cytogenetic abnormalities are frequently present and usually involve chromosome 11q23 (MLL gene).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-05A5-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-05BE-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia and Myelodysplastic Syndromes - Therapy Related","valueDescription":"Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome","ValueMeaning":{"publicId":"2836812","version":"1","preferredName":"Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome","longName":"2836812v1.00","preferredDefinition":"Acute myeloid leukemias, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms arising as a result of the mutagenic effect of chemotherapy agents and/or radiation that are used for the treatment of neoplastic or non-neoplastic disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid Neoplasm Post Cytotoxic Therapy","conceptCode":"C27912","definition":"Acute myeloid leukemias, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms arising as a result of the mutagenic effect of chemotherapy agents and/or radiation that are used for the treatment of neoplastic or non-neoplastic disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-05CB-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-05E4-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia with Multilineage Dysplasia Without Antecedent Myelodysplastic Syndrome","valueDescription":"De novo Acute Myeloid Leukemia with Multilineage Dysplasia","ValueMeaning":{"publicId":"2590749","version":"1","preferredName":"De novo Acute Myeloid Leukemia with Multilineage Dysplasia","longName":"2590749v1.00","preferredDefinition":"An acute myeloid leukemia arising de novo and not as a result of treatment. It is characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines. Patients often present with severe cytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Multilineage Dysplasia","conceptCode":"C9289","definition":"An acute myeloid leukemia arising de novo and not as a result of treatment. It is characterized by the presence of myelodysplastic features in at least 50% of the cells of at least two hematopoietic cell lines. Patients often present with severe cytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F3CBD2-03B7-469E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-061F-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia with Multilineage Dysplasia Following Myelodysplastic Syndrome Or Myeloproliferative Disorder","valueDescription":"Acute Myeloid Leukemia with Multilineage Dysplasia following Myelodysplastic Syndrome","ValueMeaning":{"publicId":"2590747","version":"1","preferredName":"Acute Myeloid Leukemia with Multilineage Dysplasia following Myelodysplastic Syndrome","longName":"2590747","preferredDefinition":"A subtype of acute myeloid leukemia with multilineage dysplasia.  This subtype includes the vast majority of refractory anemia with excess blasts in transformation cases.  This latter term used to be part of the French-American-British classification scheme of myelodysplastic syndromes and has been eliminated from the WHO classification.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome","conceptCode":"C4037","definition":"An acute myeloid leukemia developing in patients with a prior history of myelodysplastic syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27F3CBD2-0390-469E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-0634-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia with Multilineage Dysplasia","valueDescription":"Acute Myeloid Leukemia with Multilineage Dysplasia","ValueMeaning":{"publicId":"2672714","version":"1","preferredName":"Acute Myeloid Leukemia with Multilineage Dysplasia","longName":"2672714","preferredDefinition":"An acute myeloid leukemia (AML) with at least 20% blasts in the marrow or blood, and dysplasia in 2 or more myeloid cell lines.  Dysplasia must be present in at least 50% of the cells of at least 2 cell lines.  Patients with this type of AML often present with severe cytopenia.  The presence of multilineage dysplasia has an adverse effect on the probability of achieving complete remission.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia, Myelodysplasia-Related","conceptCode":"C7600","definition":"An acute myeloid leukemia with at least 20% blasts in the bone marrow or blood, and either a previous history of myelodysplastic syndrome, multilineage dysplasia or myelodysplastic syndrome-related cytogenetic abnormalities.  There is no history of prior cytotoxic therapy for an unrelated disorder, and there is absence of the molecular abnormalities that are present in acute myeloid leukemia with recurrent genetic abnormalities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37BBBFE3-F0E5-60D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-063F-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Promyelocytic Leukemia t(15;17)(q22;q12) and Variants","valueDescription":"Acute Promyelocytic Leukemia with t(15;17)(q22;q12)(PML/RARa)","ValueMeaning":{"publicId":"2672716","version":"1","preferredName":"Acute Promyelocytic Leukemia with t(15;17)(q22;q12)(PML/RARa)","longName":"2672716","preferredDefinition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate.  It is characterized by the t(15;17)(q22;q12) translocation.  There are two variants: the typical and the microgranular (hypogranular) variants.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Promyelocytic Leukemia with t(15;17)(q22;q12)(PML/RARa)","conceptCode":"C36259","definition":"An acute myeloid leukemia (AML) in which abnormal promyelocytes predominate.  It is characterized by the t(15;17)(q22;q12) translocation.  There are two variants: the typical and the microgranular (hypogranular) variants.  This AML is particularly sensitive to treatment with all trans-retinoic acid and has a favorable prognosis.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"37BBBFE3-F122-60D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-0655-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Acute Myeloid Leukemia With Recurrent Genetic Abnormalities","valueDescription":"Acute Myeloid Leukemia with Recurrent Genetic Abnormalities","ValueMeaning":{"publicId":"2836816","version":"1","preferredName":"Acute Myeloid Leukemia with Recurrent Genetic Abnormalities","longName":"2836816","preferredDefinition":"A group of acute myeloid leukemias (AMLs) characterized by recurrent genetic abnormalities, mainly balanced translocations.  This group of AMLs often has a high rate of complete remission, and favorable prognosis.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with Recurrent Genetic Abnormalities","conceptCode":"C7175","definition":"A group of acute myeloid leukemias characterized by recurrent genetic abnormalities, mainly balanced translocations.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-0663-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-067C-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Adenosquamous Carcinoma","valueDescription":"Adenosquamous Carcinoma","ValueMeaning":{"publicId":"2836818","version":"1","preferredName":"Adenosquamous Carcinoma","longName":"2836818","preferredDefinition":"A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenosquamous Carcinoma","conceptCode":"C3727","definition":"An invasive carcinoma composed of malignant glandular cells and malignant squamous cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-0687-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-06A0-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Aggressive NK-Cell Leukemia","valueDescription":"Aggressive NK-Cell Leukemia","ValueMeaning":{"publicId":"2836819","version":"1","preferredName":"Aggressive NK-Cell Leukemia","longName":"2836819","preferredDefinition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia/lymphoma, also known as aggressive NK-cell leukemia/lymphoma, it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas.  It affects primarily teenagers and young adults.  It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.--2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aggressive NK-Cell Leukemia","conceptCode":"C8647","definition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-06AB-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-06C4-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Adult T-Cell Leukemia Or Lymphoma","valueDescription":"Adult T-Cell Lymphoma/Leukemia","ValueMeaning":{"publicId":"2836820","version":"1","preferredName":"Adult T-Cell Lymphoma/Leukemia","longName":"2836820","preferredDefinition":"A peripheral (mature) T-cell neoplasm caused by the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell lymphoma/leukemia is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adult T-Cell Leukemia/Lymphoma","conceptCode":"C3184","definition":"A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-06CE-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-06E7-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"AML With Abnormal Bone Marrow Eosinophil Inv(16) or t(16;16) or t(16;16)(p13;q22)(CBF Beta/MHY11)","valueDescription":"Acute Myeloid Leukemia with inv(16)(p13;q22)","ValueMeaning":{"publicId":"2836822","version":"1","preferredName":"Acute Myeloid Leukemia with inv(16)(p13;q22)","longName":"2836822v1.00","preferredDefinition":"Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) which results in the expression of the fusion protein CBFB-MYH11.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11","conceptCode":"C9018","definition":"Acute myeloid leukemia characterized by the presence of abnormal bone marrow eosinophils and the characteristic cytogenetic abnormality inv(16)(p13.1q22) which results in the expression of the fusion protein CBFB-MYH11.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-06F5-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-070E-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"AML with 11q23 (MLL) abnormality","valueDescription":"Acute Myeloid Leukemia with 11q23 (MLL) Abnormalities","ValueMeaning":{"publicId":"2836823","version":"1","preferredName":"Acute Myeloid Leukemia with 11q23 (MLL) Abnormalities","longName":"2836823","preferredDefinition":"An acute myeloid leukemia (AML) usually associated with monocytic features.  Patients may present with disseminated intravascular coagulation.  This AML has an intermediate survival.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia with a Variant KMT2A Rearrangement","conceptCode":"C6924","definition":"A term referring to acute myeloid leukemias with rearrangement of the KMT2A gene that results in translocations with various genes other than the MLLT3 (AF9) gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-0718-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-0731-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Aggressive Systemic Mastocytosis","valueDescription":"Aggressive Systemic Mastocytosis","ValueMeaning":{"publicId":"2836825","version":"1","preferredName":"Aggressive Systemic Mastocytosis","longName":"2836825","preferredDefinition":"An aggressive and progressive mast cell neoplasm characterized by systemic infiltration of internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinical symptoms include hepatomegaly, splenomegaly, portal hypertension, malabsorption syndrome, and pathologic fractures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aggressive Systemic Mastocytosis","conceptCode":"C9285","definition":"An aggressive and progressive mast cell neoplasm characterized by systemic infiltration of internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinical symptoms include hepatomegaly, splenomegaly, portal hypertension, malabsorption syndrome, and pathologic fractures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62470ADA-073E-83FB-E040-BB89AD436FBF","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"KUMMEROA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62470ADA-0757-83FB-E040-BB89AD436FBF","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Primitive Neuroectodermal Tumor (PNET)","valueDescription":"Primitive Neuroectodermal Tumor","ValueMeaning":{"publicId":"2838710","version":"1","preferredName":"Primitive Neuroectodermal Tumor","longName":"2838710","preferredDefinition":"A malignant neoplasm that originates in the neuroectoderm. The neuroectoderm constitutes the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems and includes some glial cell precursors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primitive Neuroectodermal Tumor","conceptCode":"C3716","definition":"A malignant neoplasm that originates in the neuroectoderm. The neuroectoderm constitutes the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems and includes some glial cell precursors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A7EC44-0A4C-AA83-E040-BB89AD437747","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A7EC44-0A65-AA83-E040-BB89AD437747","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Primary Effusion Lymphoma","valueDescription":"Primary Effusion Lymphoma","ValueMeaning":{"publicId":"2838711","version":"1","preferredName":"Primary Effusion Lymphoma","longName":"2838711","preferredDefinition":"An aggressive non-Hodgkin B-cell lymphoma composed of large cells, presenting as a serous effusion without detectable tumor masses.  It is universally associated with human herpes virus 8 (HHV-8)/Kaposi sarcoma herpes virus (KSHV) [HHV-8/KSHV].  It mostly occurs in the setting of immunodeficiency; most cases have been reported in HIV positive patients.  The most common sites of involvement are the pleural, pericardial, and peritoneal cavities.  The prognosis is extremely unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Effusion Lymphoma","conceptCode":"C6915","definition":"A large B-cell lymphoma usually presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. Rare HHV8-positive lymphomas indistinguishable from primary effusion lymphomas (PEL) present as solid tumor masses, and have been termed extracavitary PEL. The prognosis is extremely unfavorable. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A7EC44-0A6F-AA83-E040-BB89AD437747","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A7EC44-0A88-AA83-E040-BB89AD437747","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Schwannoma - Melanotic","valueDescription":"Melanocytic Schwannoma","ValueMeaning":{"publicId":"2838761","version":"1","preferredName":"Melanocytic Schwannoma","longName":"2838761","preferredDefinition":"Melanotic Schwannoma (also called Melanotic Neurilemmoma or Melanotic Neurinoma) is a rare type of Schwannoma which is circumscribed, pigmented and composed of cells with the ultrastructure and immunophenotype of Schwann cells, but which contain melanosomes that are reactive for melanoma markers. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanotic Schwannoma","conceptCode":"C6970","definition":"A rare circumscribed, non-encapsulated and grossly pigmented nerve sheath tumor. It is composed of cells with the immunophenotypic and electron microscopic features of Schwann cells which contain melanosomes and are positive for melanoma markers. It usually involves spinal nerve roots but may occur in other locations. It may be associated with PRKAR1A gene mutation and Carney complex. Malignant behavior has been reported in a significant number of patients.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A85C92-1296-B23A-E040-BB89AD431D54","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A85C92-12AF-B23A-E040-BB89AD431D54","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Schwannoma - Cellular","valueDescription":"Cellular Schwannoma","ValueMeaning":{"publicId":"2838763","version":"1","preferredName":"Cellular Schwannoma","longName":"2838763","preferredDefinition":"Cellular Schwannoma (also called Cellular Neurilemmoma or Cellular Neurinoma) is a hypercellular Schwannoma composed exclusively or predominantly of Antoni A tissue, and devoid of Verocay bodies. Cellular Schwannomas are benign, although recurrences can occur, especially when located in the spine. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cellular Schwannoma","conceptCode":"C4724","definition":"A morphologic variant of schwannoma characterized by hypercellularity, Antoni A pattern, and the absence of well-formed Verocay bodies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A85C92-12BC-B23A-E040-BB89AD431D54","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A85C92-12D5-B23A-E040-BB89AD431D54","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Sarcomatoid Carcinoma","valueDescription":"Sarcomatoid Carcinoma","ValueMeaning":{"publicId":"2838764","version":"1","preferredName":"Sarcomatoid Carcinoma","longName":"2838764","preferredDefinition":"Cancer that arises in cells that appear spindle-shaped when viewed under a microscope. These cancers can occur in various places in the body, including the skin, lungs, kidney, breast, gastrointestinal tract, bone, and muscle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcomatoid Carcinoma","conceptCode":"C27004","definition":"A malignant epithelial neoplasm characterized by the presence of spindle cells and anaplastic morphologic features.  Giant cells and a sarcomatous component may also be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A85C92-12DF-B23A-E040-BB89AD431D54","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A85C92-12F8-B23A-E040-BB89AD431D54","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Adenoid Cystic Carcinoma","valueDescription":"Adenoid Cystic Carcinoma","ValueMeaning":{"publicId":"2836817","version":"1","preferredName":"Adenoid Cystic Carcinoma","longName":"2836817","preferredDefinition":"A malignant tumor arising from the epithelial cells, also known as cylindroma.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoid Cystic Carcinoma","conceptCode":"C2970","definition":"A malignant tumor arising from the epithelial cells.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"624748BE-AA6A-D571-E040-BB89AD4336CB","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"624748BE-AA83-D571-E040-BB89AD4336CB","beginDate":"2009-02-06","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","deletedIndicator":"No"},{"value":"Mucinous Adenocarcinoma","valueDescription":"Mucinous Adenocarcinoma","ValueMeaning":{"publicId":"2838623","version":"1","preferredName":"Mucinous Adenocarcinoma","longName":"2838623","preferredDefinition":"An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucinous Adenocarcinoma","conceptCode":"C26712","definition":"An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-596B-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"HARTLEYG","dateModified":"2017-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6E019-5984-F2F6-E040-BB89AD4350E9","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Mucinous","valueDescription":"Mucinous","ValueMeaning":{"publicId":"2838625","version":"1","preferredName":"Mucinous","longName":"2838625","preferredDefinition":"containing or resembling mucin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucinous","conceptCode":"C14163","definition":"Containing or resembling mucin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-5991-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6E019-59AA-F2F6-E040-BB89AD4350E9","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Mucosal-Lentiginous Melanoma","valueDescription":"Mucosal Lentiginous Melanoma","ValueMeaning":{"publicId":"2577108","version":"1","preferredName":"Mucosal Lentiginous Melanoma","longName":"2577108","preferredDefinition":"An acral lentiginous melanoma affecting mucosal surfaces.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucosal Lentiginous Melanoma","conceptCode":"C48622","definition":"An acral lentiginous melanoma affecting mucosal surfaces.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA41-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"DWARZEL","dateModified":"2006-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6E019-59CD-F2F6-E040-BB89AD4350E9","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Mucoepidermoid Carcinoma","valueDescription":"Mucoepidermoid Carcinoma","ValueMeaning":{"publicId":"2838626","version":"1","preferredName":"Mucoepidermoid Carcinoma","longName":"2838626","preferredDefinition":"A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucoepidermoid Carcinoma","conceptCode":"C3772","definition":"A carcinoma morphologically characterized the presence of cuboidal mucous cells, goblet-like mucous cells, squamoid cells, cystic changes, and a fibrotic stromal formation. It can occur in several anatomic sites, including parotid gland, oral cavity, paranasal sinus, skin, breast, lung, larynx, and lacrimal ducts. It is classified as low or high grade.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-59D8-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6E019-59F1-F2F6-E040-BB89AD4350E9","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Neoplasm Of Uncertain Lineage And Stage Of Differentiation - Blastic NK-Cell Lymphoma","valueDescription":"Blastic NK-Cell Lymphoma","ValueMeaning":{"publicId":"2838635","version":"1","preferredName":"Blastic NK-Cell Lymphoma","longName":"2838635","preferredDefinition":"An aggressive immature hematologic neoplasm formerly known as blastic NK cell lymphoma, composed of cells with a lymphoblast-like morphology.  Recent evidence suggests derivation from a plasmacytoid monocyte.  Patients present with cutaneous tumors and bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blastic Plasmacytoid Dendritic Cell Neoplasm","conceptCode":"C7203","definition":"A clinically aggressive neoplasm derived from the precursors of plasmacytoid dendritic cells (also called professional type I interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-59FC-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2016-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6E019-5A15-F2F6-E040-BB89AD4350E9","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Neurotropic Melanoma","valueDescription":"Desmoplastic Neurotropic Melanoma","ValueMeaning":{"publicId":"2838637","version":"1","preferredName":"Desmoplastic Neurotropic Melanoma","longName":"2838637","preferredDefinition":"A desmoplastic melanoma characterized by the presence of nerve infiltration by atypical spindled melanocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desmoplastic Neurotropic Melanoma","conceptCode":"C48614","definition":"A desmoplastic melanoma characterized by the presence of nerve infiltration by atypical spindled melanocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-5A38-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6E019-5A51-F2F6-E040-BB89AD4350E9","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Neurofibroma - Plexiform","valueDescription":"Plexiform Neurofibroma","ValueMeaning":{"publicId":"2838639","version":"1","preferredName":"Plexiform Neurofibroma","longName":"2838639","preferredDefinition":"An elongated and multinodular neurofibroma, formed when the tumor involves either multiple trunks of a plexus or multiple fascicles of a large nerve, such as the sciatic. Some plexiform neurofibromas resemble a bag of worms, others produce a massive ropy enlargement of the nerve. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plexiform Neurofibroma","conceptCode":"C3797","definition":"An elongated and multinodular neurofibroma, formed when the tumor involves either multiple trunks of a plexus or multiple fascicles of a large nerve, such as the sciatic. Some plexiform neurofibromas resemble a bag of worms, others produce a massive ropy enlargement of the nerve. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-5A5E-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6E019-5A77-F2F6-E040-BB89AD4350E9","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Neurofibroma - Not Otherwise Characterized","valueDescription":"Neurofibroma","ValueMeaning":{"publicId":"2838641","version":"1","preferredName":"Neurofibroma","longName":"2838641","preferredDefinition":"An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neurofibroma","conceptCode":"C3272","definition":"An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths. It is composed of perineurial-like fibroblasts and Schwann cells. It usually presents as a localized cutaneous lesion and less often as a circumscribed peripheral nerve mass. Patients with neurofibromatosis type 1 present with multiple masses. Neurofibromas which arise from major nerves and plexiform neurofibromas are precursor lesions to malignant peripheral nerve sheath tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-5A84-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6E019-5A9D-F2F6-E040-BB89AD4350E9","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Neuroblastoma","valueDescription":"Neuroblastoma","ValueMeaning":{"publicId":"2573075","version":"1","preferredName":"Neuroblastoma","longName":"2573075","preferredDefinition":"Neuroblastoma is a specific type of neuroblastic tumor which is characterized by the presense of neuroblastic cells forming groups or nests separated by delicate stromal septa without prominent Schwannian stroma. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroblastoma","conceptCode":"C3270","definition":"A malignant neuroblastic tumor characterized by the presence of neuroblastic cells, the absence of ganglion cells, and the absence of a prominent Schwannian stroma formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA80-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-04","endDate":null,"createdBy":"KLINGERK","dateCreated":"2005-02-04","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6E019-5AA7-F2F6-E040-BB89AD4350E9","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Nodal Marginal Zone B-Cell Lymphoma","valueDescription":"Nodal Marginal Zone B-Cell Lymphoma","ValueMeaning":{"publicId":"2838642","version":"1","preferredName":"Nodal Marginal Zone B-Cell Lymphoma","longName":"2838642","preferredDefinition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodal Marginal Zone Lymphoma","conceptCode":"C8863","definition":"A primary nodal B-cell non-Hodgkin lymphoma which morphologically resembles lymph nodes involved by marginal zone lymphomas of extranodal or splenic types, but without evidence of extranodal or splenic disease.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-5AB3-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6E019-5ACC-F2F6-E040-BB89AD4350E9","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblast","valueDescription":"Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblasts","ValueMeaning":{"publicId":"2738442","version":"1","preferredName":"Refractory Cytopenia with Multilineage Dysplasia and Ringed Sideroblasts","longName":"2738442","preferredDefinition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia, dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines, and 15% or more ringed sideroblasts in the bone marrow.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia","conceptCode":"C27726","definition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia, dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines, and 15% or more ring sideroblasts in the bone marrow.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BDA45E-EC12-65D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A80A49-007D-95C0-E040-BB89AD43324B","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Refractory Cytopenia With Multilineage Dysplasia","valueDescription":"Refractory Cytopenia with Multilineage Dysplasia","ValueMeaning":{"publicId":"2771858","version":"1","preferredName":"Refractory Cytopenia with Multilineage Dysplasia","longName":"2771858","preferredDefinition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia and dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines.  A minority of cases progress to acute myeloid leukemia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome, Not Otherwise Specified with Multilineage Dysplasia","conceptCode":"C8574","definition":"A myelodysplastic syndrome characterized by bi-cytopenia or pancytopenia and dysplastic changes in 10% or more of the cells in two or more of the myeloid cell lines. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF67-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A80A49-0092-95C0-E040-BB89AD43324B","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Refractory Anemia with Ringed Sideroblasts","valueDescription":"Refractory Anemia with Ringed Sideroblasts","ValueMeaning":{"publicId":"2771857","version":"1","preferredName":"Refractory Anemia with Ringed Sideroblasts","longName":"2771857","preferredDefinition":"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ringed sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain.  It occurs primarily in older individuals.  The median survival exceeds 5 years.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with Ring Sideroblasts","conceptCode":"C4036","definition":"A myelodysplastic syndrome characterized by an anemia in which 15% or more of the erythroid precursors are ring sideroblasts.  The ring sideroblast is an erythroid precursor in which one third or more of the nucleus is encircled by granules which are positive for iron stain. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AF42-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A80A49-009D-95C0-E040-BB89AD43324B","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Refractory Anemia With Exess Blasts (RAEB) - 2","valueDescription":"RAEB-2","ValueMeaning":{"publicId":"2582030","version":"1","preferredName":"RAEB-2","longName":"2582030","preferredDefinition":"A myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood. Approximately 33% of cases progress to acute leukemia.  The prognosis is usually poor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome/Acute Myeloid Leukemia","conceptCode":"C7168","definition":"A myelodysplastic syndrome characterized by the presence of dysplasia in one or more hematopoietic cell lineages and 10-19% blasts in bone marrow or peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0D7B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":"Refreshed concept association to pick up correct symbol instead of  <. 12.15.17 Updated definition to match current NCIt as requested by NMDP. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A80A49-00B2-95C0-E040-BB89AD43324B","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Paget Disease without Invasive Carcinoma","valueDescription":"Paget's Disease of the Breast without Invasive Carcinoma","ValueMeaning":{"publicId":"2577126","version":"1","preferredName":"Paget's Disease of the Breast without Invasive Carcinoma","longName":"2577126","preferredDefinition":"Paget's disease involving the skin overlying the mammary gland, without accompanying invasive ductal or lobular breast carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Paget Disease without Invasive Carcinoma","conceptCode":"C47858","definition":"Paget disease involving the skin overlying the mammary gland, without accompanying invasive ductal or lobular breast carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA53-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A770F5-59B5-03F5-E040-BB89AD435AD2","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A770F5-59C0-03F5-E040-BB89AD435AD2","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Oligodendroglioma - Not Otherwise Characterized","valueDescription":"Oligodendroglioma","ValueMeaning":{"publicId":"2838655","version":"1","preferredName":"Oligodendroglioma","longName":"2838655","preferredDefinition":"A well-differentiated (WHO grade II), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligodendroglioma","conceptCode":"C3288","definition":"A well-differentiated (WHO grade 2), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A770F5-59CD-03F5-E040-BB89AD435AD2","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A770F5-59E6-03F5-E040-BB89AD435AD2","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Pineoblastoma","valueDescription":"Pineoblastoma","ValueMeaning":{"publicId":"2578700","version":"1","preferredName":"Pineoblastoma","longName":"2578700","preferredDefinition":"Pineoblastoma (WHO grade IV) is a highly malignant, primitive embryonal neoplasm, which occurs more commonly in children. It is composed of patternless sheets of densely packed small cells with round-to-irregular nuclei and scant cytoplasm, similar to medulloblastoma and related primitive neuroectodermal tumors. A frequent complication is metastasis via cerebrospinal fluid pathways, which is often associated with a fatal outcome. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pineoblastoma","conceptCode":"C9344","definition":"A poorly differentiated malignant embryonal neoplasm arising from the pineal region.  It usually occurs in children and it is characterized by the presence of small immature neuroepithelial cells.  It may follow an aggressive clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0079-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A770F5-59F1-03F5-E040-BB89AD435AD2","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Pineal Parenchymal Tumor Of Intermediate Differentiation","valueDescription":"Pineal Parenchymal Tumor of Intermediate Differentiation","ValueMeaning":{"publicId":"2838665","version":"1","preferredName":"Pineal Parenchymal Tumor of Intermediate","longName":"2838665v1.00","preferredDefinition":"A WHO grade 2 or 3 pineal parenchymal neoplasm of intermediate-grade malignancy, affecting all ages.  It is composed of diffuse sheets or large lobules of uniform cells with mild to moderate nuclear atypia and low to moderate level mitotic activity.  (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pineal Parenchymal Tumor of Intermediate Differentiation","conceptCode":"C6967","definition":"A WHO grade 2 or 3 pineal parenchymal neoplasm of intermediate-grade malignancy, affecting all ages.  It is composed of diffuse sheets or large lobules of uniform cells with mild to moderate nuclear atypia and low to moderate level mitotic activity.  (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A770F5-59FF-03F5-E040-BB89AD435AD2","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A770F5-5A18-03F5-E040-BB89AD435AD2","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Papillary","valueDescription":"Papillary","ValueMeaning":{"publicId":"2738824","version":"1","preferredName":"Papillary","longName":"2738824","preferredDefinition":"of or relating to or resembling papilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary","conceptCode":"C14166","definition":"Of or relating to or resembling papilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49F8B2D6-A892-712E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"JONSDOTTIRT","dateCreated":"2008-04-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A770F5-5A22-03F5-E040-BB89AD435AD2","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Pineocytoma","valueDescription":"Pineocytoma","ValueMeaning":{"publicId":"2578715","version":"1","preferredName":"Pineocytoma","longName":"2578715","preferredDefinition":"Pineocytoma (WHO grade II) is a slow growing tumor, more common in young adults. It is composed of small, uniform, mature cells resembling pineocytes with occasional large pineocytomatous rosettes.  It may show a wide range of divergent phenotypes, including neuronal, glial, melanocytic, photoreceptor and mesenchymal differentiation. Pineocytoma generally has a relatively favorable prognosis. (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pineocytoma","conceptCode":"C6966","definition":"A WHO grade 1 slow growing tumor, more frequently affecting young adults. It is composed of small, uniform, mature cells resembling pineocytes with occasional large pineocytomatous rosettes. It may show a wide range of divergent phenotypes, including neuronal, glial, melanocytic, photoreceptor and mesenchymal differentiation. Pineocytoma generally has a relatively favorable prognosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0088-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A770F5-5A2E-03F5-E040-BB89AD435AD2","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Meningioma - Anaplastic","valueDescription":"Anaplastic (Malignant) Meningioma","ValueMeaning":{"publicId":"2578436","version":"1","preferredName":"Anaplastic (Malignant) Meningioma","longName":"2578436","preferredDefinition":"A WHO grade III meningioma exhibiting histological features of frank malignancy that exceed the abnormalities present in atypical meningioma. Anaplastic meningiomas are usually fatal, with median survival of less than 2 years. (Adapted from WHO 2000.) - 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic (Malignant) Meningioma","conceptCode":"C4051","definition":"A WHO grade III meningioma characterized by the presence of malignant morphologic features, including malignant cytology and a very high mitotic index (20 or more mitoses per ten high power fields).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FF71-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-31","modifiedBy":"ONEDATA","dateModified":"2006-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AF85-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Malignant Peripheral Nerve Sheath Tumor (MPNST) - Epithelioid","valueDescription":"Epithelioid Malignant Peripheral Nerve Sheath Tumor","ValueMeaning":{"publicId":"2838599","version":"1","preferredName":"Epithelioid Malignant Peripheral Nerve Sheath Tumor","longName":"2838599","preferredDefinition":"Epithelioid MPNST is a rare variant defined as Malignant Peripheral Nerve Sheath Tumor with a predominance of epithelioid cells. They show no association with NF1. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epithelioid Malignant Peripheral Nerve Sheath Tumor","conceptCode":"C6561","definition":"A rare variant of malignant peripheral nerve sheath tumor composed predominantly or exclusively of epithelioid cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-ADEA-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AE03-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Malignant Lymphoma","valueDescription":"Lymphoma","ValueMeaning":{"publicId":"2838600","version":"1","preferredName":"Lymphoma","longName":"2838600","preferredDefinition":"A malignant (clonal) proliferation of B- or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites.  This category includes Non-Hodgkin's lymphomas and Hodgkin's lymphomas. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE0D-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AE26-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Mast Cell Sarcoma","valueDescription":"Mast Cell Sarcoma","ValueMeaning":{"publicId":"2838602","version":"1","preferredName":"Mast Cell Sarcoma","longName":"2838602","preferredDefinition":"A rare entity characterized by localized but destructive growth of a tumor consisting of highly atypical, immature mast cells.(WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mast Cell Sarcoma","conceptCode":"C9348","definition":"A rare malignant neoplasm characterized by localized but destructive growth of a tumor consisting of highly atypical, immature mast cells. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE34-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AE4D-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Mast Cell Leukemia","valueDescription":"Mast Cell Leukemia","ValueMeaning":{"publicId":"2590857","version":"1","preferredName":"Mast Cell Leukemia","longName":"2590857","preferredDefinition":"A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mast Cell Leukemia","conceptCode":"C3169","definition":"A variant of systemic mastocytosis with involvement of the bone marrow (20% or more mast cells) and the peripheral blood (mast cells account for 10% or more of peripheral blood white cells). (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28446C9F-B55A-188F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AE57-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Mantle Cell Lymphoma","valueDescription":"Mantle Cell Lymphoma","ValueMeaning":{"publicId":"2838603","version":"1","preferredName":"Mantle Cell Lymphoma","longName":"2838603","preferredDefinition":"An aggressive, usually diffuse non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes).  Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement.  The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma.  The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mantle Cell Lymphoma","conceptCode":"C4337","definition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE62-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AE7B-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Malignant Peripheral Nerve Sheath Tumor (MPNST) - Not Otherwise Characterized","valueDescription":"Malignant Peripheral Nerve Sheath Tumor","ValueMeaning":{"publicId":"2838605","version":"1","preferredName":"Malignant Peripheral Nerve Sheath Tumor","longName":"2838605","preferredDefinition":"An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Peripheral Nerve Sheath Tumor","conceptCode":"C3798","definition":"An uncommon, highly aggressive malignant tumor, arising from the peripheral nerves and affecting mostly adults in their third to sixth decades of life.  It usually occurs in medium-sized and large nerves of the buttock, thigh, upper arm, or the paraspinal region.  It may be associated with neurofibromatosis 1 (NF1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE88-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AEA1-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Medullary","valueDescription":"Adrenal Medulla","ValueMeaning":{"publicId":"2838608","version":"1","preferredName":"Adrenal Medulla","longName":"2838608","preferredDefinition":"The inner part of the adrenal gland; it synthesizes, stores and releases catecholamines. (MeSH)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenal Medulla","conceptCode":"C12397","definition":"The inner region of the adrenal gland. The adrenal medulla produces, stores, and secretes epinephrine and norepinephrine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AED2-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AEEB-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Mediastinal (Thymic) Large B-Cell Lymphoma","valueDescription":"Mediastinal (Thymic) Large B-Cell Lymphoma","ValueMeaning":{"publicId":"2838609","version":"1","preferredName":"Mediastinal (Thymic) Large B-Cell Lymphoma","longName":"2838609","preferredDefinition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Mediastinal Large B-Cell Lymphoma","conceptCode":"C9280","definition":"A large B-cell non-Hodgkin lymphoma arising in the mediastinum.  Morphologically it is characterized by a massive diffuse lymphocytic proliferation associated with compartmentalizing fibrosis.  Response to intensive chemotherapy, with or without radiotherapy, is usually good. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AEF5-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SOKKERL","dateModified":"2018-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AF0E-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Meningioma - Chordoid","valueDescription":"Chordoid Meningioma","ValueMeaning":{"publicId":"2838611","version":"1","preferredName":"Chordoid Meningioma","longName":"2838611","preferredDefinition":"A WHO grade II meningioma with regions that are histologically similar to chordoma, with trabecula of eosinophilic, vacuolated cells in a myxoid background. Chordoid meningiomas have a high rate of recurrence following subtotal resection. (Adapted from WHO 2000.) - 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chordoid Meningioma","conceptCode":"C6908","definition":"A WHO grade II, usually recurring meningioma characterized by the predominance of tissues that are histologically similar to chordoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AF32-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AF4B-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Meningioma - Atypical","valueDescription":"Atypical Meningioma","ValueMeaning":{"publicId":"2838613","version":"1","preferredName":"Atypical Meningioma","longName":"2838613","preferredDefinition":"A WHO grade II meningioma with increased mitotic activity or three or more of the following features: increased cellularity, small cells with high nuclear to cytoplasm ratio, prominent nucleoli, uninterrupted patternless or sheet-like growth, and foci of spontaneous or geographic necrosis. (Adapted from WHO 2000.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Meningioma","conceptCode":"C4723","definition":"A WHO grade II meningioma characterized by the presence of brain invasion and an increased mitotic activity, or at least three of the following morphologic features: small cells, high cellularity, prominent nucleoli, lack of architectural pattern, and necrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AF58-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AF71-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Medulloblastoma - Melanotic","valueDescription":"Melanotic medulloblastoma","ValueMeaning":{"publicId":"2568655","version":"1","preferredName":"Melanotic medulloblastoma","longName":"2568655","preferredDefinition":"Melanotic Medulloblastoma (WHO grade IV) is a rare tumor of childhood with a predominant element of small round cells closely resembling classic medulloblastoma and a minor component of melanin-forming neuroepithelial cells. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanocytic Medulloblastoma","conceptCode":"C9497","definition":"A rare malignant embryonal neoplasm characterized by the presence of small cells which resemble the cells of classic medulloblastoma and a minor population of melanin-forming neuroepithelial cells.  It usually has an unfavorable clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D93C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-11","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2004-03-11","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AF9A-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Medulloblastoma - Large Cell","valueDescription":"Large Cell Medulloblastoma","ValueMeaning":{"publicId":"2578725","version":"1","preferredName":"Large Cell Medulloblastoma","longName":"2578725","preferredDefinition":"Large Cell Medulloblastoma is a variant of Medulloblastoma (about 4% of cases). Some features of the tumor cells are large, round and/or pleomorphic nuclei with prominent nucleoli and a more abundant cytoplasm than that found in the classic medulloblastoma. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Large Cell Medulloblastoma","conceptCode":"C6904","definition":"A medulloblastoma composed of large cells with prominent nucleoli and a larger amount of cytoplasm in contrast with the cells of the classic medulloblastoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0092-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"ONEDATA","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AFAF-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Medulloblastoma - Desmoplastic","valueDescription":"Desmoplastic medulloblastoma","ValueMeaning":{"publicId":"2578724","version":"1","preferredName":"Desmoplastic medulloblastoma","longName":"2578724","preferredDefinition":"Desmoplastic Medulloblastoma is a variant of Medulloblastoma. Some histologic features of this lesion include nodular, reticulin-free zones ('pale islands') surrounded by densely packed, highly proliferative cells that produce a dense intercellular reticulin fiber network. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desmoplastic/Nodular Medulloblastoma","conceptCode":"C4956","definition":"A medulloblastoma characterized by the presence of nodular, collagenous areas which do not contain reticulin, surrounded by hypercellular areas which contain an intercellular reticulin fiber network.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0091-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-03-11","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2004-03-11","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AFC4-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Malignant Peripheral Nerve Sheath Tumor (MPNST) - Melanotic","valueDescription":"Malignant Melanocytic Peripheral Nerve Sheath Tumor","ValueMeaning":{"publicId":"2838597","version":"1","preferredName":"Malignant Melanocytic Peripheral Nerve Sheath Tumor","longName":"2838597","preferredDefinition":"Melanotic MPNST is a rare variant of Malignant Peripheral Nerve Sheath Tumor (MPNST).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Melanotic Peripheral Nerve Sheath Tumor","conceptCode":"C4748","definition":"A rare variant of malignant peripheral nerve sheath tumor.  It is characterized by the presence of malignant cells that contain melanin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-ADC4-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-AFD9-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Meningioma - Papillary","valueDescription":"Papillary Meningioma","ValueMeaning":{"publicId":"2838615","version":"1","preferredName":"Papillary Meningioma","longName":"2838615","preferredDefinition":"A rare WHO grade III meningioma defined by the presence of a perivascular pseudopapillary pattern in at least part of the tumor. They are clinically aggressive. (Adapted from WHO 2000.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Meningioma","conceptCode":"C3904","definition":"A WHO grade III meningioma characterized by the predominance of a perivascular pseudopapillary pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AFE7-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B000-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Meningioma - Not Otherwise Characterized","valueDescription":"Meningioma","ValueMeaning":{"publicId":"2572989","version":"1","preferredName":"Meningioma","longName":"2572989","preferredDefinition":"Meningiomas (mostly WHO grade I, with some WHO grade II or III) are generally slow growing, benign tumors attached to the dura mater and are composed of neoplastic meningothelial (arachnoidal) cells. They typically occur in adults, often women. Meningiomas have a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meningioma","conceptCode":"C3230","definition":"A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade 1 tumors, and some are WHO grade 2 or 3 tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA2A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-03-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B014-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Meningioma - Clear Cell","valueDescription":"Clear Cell Meningioma","ValueMeaning":{"publicId":"2838617","version":"1","preferredName":"Clear Cell Meningioma","longName":"2838617","preferredDefinition":"A WHO grade II morphologic variant of meningioma characterized by the presence of clear glycogen-rich polygonal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clear Cell Meningioma","conceptCode":"C4722","definition":"A WHO grade II morphologic variant of meningioma characterized by the presence of clear glycogen-rich polygonal cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-B022-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B03B-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Mixed Acinar-Endocrine Carcinoma","valueDescription":"Mixed Acinar-Endocrine Carcinoma","ValueMeaning":{"publicId":"2581796","version":"1","preferredName":"Mixed Acinar-Endocrine Carcinoma","longName":"2581796v1.00","preferredDefinition":"A carcinoma that arises from the pancreas showing a mixture of acinar and neuroendocrine malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Mixed Acinar-Neuroendocrine Carcinoma","conceptCode":"C6878","definition":"A carcinoma that arises from the pancreas showing a mixture of acinar and neuroendocrine malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C91-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-10","modifiedBy":"KUMMEROA","dateModified":"2023-08-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B046-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Minimal Deviation (Nevoid) Melanoma","valueDescription":"Minimal Deviation Melanoma ","ValueMeaning":{"publicId":"2581202","version":"1","preferredName":"Minimal Deviation Melanoma ","longName":"2581202","preferredDefinition":"A melanocytic neoplasm displaying morphologic features that are intermediate between those of benign nevus and melanoma. It is characterized by a nodular architectural growth resembling a melanoma, and a loss of nevus cell maturation. The melanocytic cells forming the nodular growth are uniform, and they may display a high mitotic rate, but they do not show cytologic atypia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minimal Deviation Melanoma","conceptCode":"C48612","definition":"A melanocytic neoplasm displaying morphologic features that are intermediate between those of benign nevus and melanoma.  It is characterized by a nodular architectural growth resembling a melanoma, and a loss of nevus cell maturation.  The melanocytic cells forming the nodular growth are uniform, and they may display a high mitotic rate, but they do not show cytologic atypia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A3F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B05B-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Meningioma - Rhabdoid","valueDescription":"Rhabdoid Meningioma","ValueMeaning":{"publicId":"2838619","version":"1","preferredName":"Rhabdoid Meningioma","longName":"2838619","preferredDefinition":"An uncommon WHO grade III meningioma containing patches or extensive sheets of rhabdoid cells. Rhabdoid cells are rounded tumor cells with eccentric nuclei, often with a prominent nucleolus and prominent inclusion-like eosinophilic cytoplasm comprised of whorled intermediate filaments. Rhabdoid Meningiomas typically display an aggressive clinical course. (Adapted from WHO 2000.) - 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rhabdoid Meningioma","conceptCode":"C6909","definition":"A WHO grade III meningioma characterized by the predominant presence of rhabdoid cells forming sheets.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-B069-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B082-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Monoclonal Gammopathy Of Undetermined Significance (MGUS)","valueDescription":"Monoclonal Gammopathy of Undetermined Significance","ValueMeaning":{"publicId":"2838621","version":"1","preferredName":"Monoclonal Gammopathy of Undetermined Significance","longName":"2838621","preferredDefinition":"A plasma cell disorder in which an abnormal amount of a single immunoglobulin is present in the serum. Up to 25% of cases of monoclonal gammopathy of undetermined significance (MGUS) progress to a B-cell malignancy or myeloma. MGUS may occur in conjunction with various carcinomas, chronic inflammatory and infectious conditions, and other diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Gammopathy of Undetermined Significance","conceptCode":"C3996","definition":"A condition in which an abnormal amount of a single immunoglobulin is present in the serum. This category includes IgM monoclonal gammopathy of undetermined significance and non-IgM monoclonal gammopathy of undetermined significance. Up to 25% of cases of monoclonal gammopathy of undetermined significance  progress to a B-cell malignancy or myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-B0A2-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B0BB-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Mixed Germ Cell Tumor","valueDescription":"Mixed Germ Cell Tumor","ValueMeaning":{"publicId":"2838622","version":"1","preferredName":"Mixed Germ Cell Tumor","longName":"2838622v1.00","preferredDefinition":"A malignant germ cell tumor characterized by the presence of at least two different germ cell tumor components. The different germ cell tumor components include choriocarcinoma, embryonal carcinoma, yolk sac tumor, teratoma, and seminoma. It occurs in the ovary, testis, and extragonadal sites including central nervous system and mediastinum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Germ Cell Tumor","conceptCode":"C4290","definition":"A malignant germ cell tumor characterized by the presence of at least two different germ cell tumor components. The different germ cell tumor components include choriocarcinoma, embryonal carcinoma, yolk sac tumor, teratoma, and seminoma. It occurs in the ovary, testis, and extragonadal sites including central nervous system and mediastinum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-B0C5-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B0DE-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Mixed Ductal-Endocrine Carcinoma","valueDescription":"Mixed Ductal-Endocrine Carcinoma","ValueMeaning":{"publicId":"2574561","version":"1","preferredName":"Mixed Ductal-Endocrine Carcinoma","longName":"2574561v1.00","preferredDefinition":"A carcinoma that arises from the pancreas showing a mixture of ductal and neuroendocrine malignant cells in both the primary tumor and in the metastatic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Mixed Ductal-Neuroendocrine Carcinoma","conceptCode":"C6879","definition":"A carcinoma that arises from the pancreas showing a mixture of ductal and neuroendocrine malignant cells in both the primary tumor and in the metastatic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F04E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-22","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-04-22","modifiedBy":"KUMMEROA","dateModified":"2023-08-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B0E8-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Mixed Cellularity Classical Hodgkin Lymphoma","valueDescription":"Mixed Cellularity Hodgkin Lymphoma","ValueMeaning":{"publicId":"2593119","version":"1","preferredName":"Mixed Cellularity Hodgkin Lymphoma","longName":"2593119","preferredDefinition":"A subtype of classical Hodgkin lymphoma with a mixed inflammatory stroma containing Hodgkin and Reed-Sternberg cells.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Cellularity Classic Hodgkin Lymphoma","conceptCode":"C3517","definition":"A subtype of classic Hodgkin lymphoma with scattered Reed-Sternberg and Hodgkin cells in a diffuse or vaguely nodular mixed inflammatory background without nodular sclerosing fibrosis. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"286D4DB6-4CEB-242A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added Manually curated definition.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B0FD-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Myelodysplastic Syndrome Associated With Del(5q)","valueDescription":"Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality","ValueMeaning":{"publicId":"2738446","version":"1","preferredName":"Myelodysplastic Syndrome Associated with Isolated del (5q) Chromosome Abnormality","longName":"2738446","preferredDefinition":"A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with normal to increased, often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome with del(5q)","conceptCode":"C6867","definition":"A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5.  The number of blasts in the bone marrow and blood is <5%.  The bone marrow is usually hypercellular or normocellular with increased number of often hypolobated megakaryocytes.  The peripheral blood shows macrocytic anemia.  This syndrome occurs predominantly but not exclusively in middle age to older women.  The prognosis is good and transformation to acute leukemia is rare.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BDA45E-ED8B-65D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B17D-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Myelodysplastic Syndrome - Unclassifiable","valueDescription":"Myelodysplastic Syndrome, Unclassifiable","ValueMeaning":{"publicId":"2771859","version":"1","preferredName":"Myelodysplastic Syndrome, Unclassifiable","longName":"2771859","preferredDefinition":"A subtype of myelodysplastic syndrome which initially lacks findings appropriate for classification into any other myelodysplastic category.  There are no specific morphologic findings.  The diagnosis can be made in the following instances: 1. in cases of refractory cytopenia with unilineage dysplasia or refractory cytopenia with multilineage dysplasia but with 1% blasts in the peripheral blood;  2: in cases of myelodysplastic syndrome with unilineage dysplasia which are associated with pancytopenia; 3: in cases with persistent cytopenia (s) with 1% or fewer blasts in the blood and fewer than 5% in the bone marrow, unequivocal dysplasia in less than 10% of the cells in one or more myeloid lineages, and cytogenetic abnormalities considered as presumptive evidence of myelodysplastic syndrome. (WHO, 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome, Unclassifiable","conceptCode":"C8648","definition":"A subtype of myelodysplastic syndrome which initially lacks findings appropriate for classification into any other myelodysplastic category.  There are no specific morphologic findings.  The diagnosis can be made in the following instances: 1. in cases of refractory cytopenia with unilineage dysplasia or refractory cytopenia with multilineage dysplasia but with 1% blasts in the peripheral blood; 2: in cases of myelodysplastic syndrome with unilineage dysplasia which are associated with pancytopenia; 3: in cases with persistent cytopenia (s) with 1% or fewer blasts in the blood and fewer than 5% in the bone marrow, unequivocal dysplasia in less than 10% of the cells in one or more myeloid lineages, and cytogenetic abnormalities considered as presumptive evidence of myelodysplastic syndrome. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54340434-AFB9-4116-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"KUMMEROA","dateModified":"2022-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B192-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Myelodysplastic Or Myeloproliferative Disease - Unclassifiable","valueDescription":"Myelodysplastic/Myeloproliferative Disease, Unclassifiable","ValueMeaning":{"publicId":"2838632","version":"1","preferredName":"Myelodysplastic/Myeloproliferative Disease, Unclassifiable","longName":"2838632","preferredDefinition":"This entity includes cases that have clinical, laboratory, and morphologic features that support the diagnosis of both a myelodysplastic syndrome and a chronic myeloproliferative disorder, but do not meet the criteria for any of the other entities included in the myelodysplastic/myeloproliferative disease category.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified","conceptCode":"C27780","definition":"A myelodysplastic/myeloproliferative neoplasm that does not meet the criteria of other myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, and myeloproliferative neoplasms. It is associated with cytopenia, blasts less than 20% in bone marrow and peripheral blood, thrombocytosis, and absence of genetic abnormalities associated with myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-B1A0-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"62A6485A-B1B9-B656-E040-BB89AD437D5F","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","deletedIndicator":"No"},{"value":"Adenocarcinoma - Other Variant","valueDescription":"Other Adenocarcinoma","ValueMeaning":{"publicId":"2853378","version":"1","preferredName":"Other Adenocarcinoma","longName":"2853378","preferredDefinition":"Not otherwise specified.: carcinoma derived from glandular tissue or in which tumor cells form recognizable glandular structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"657C1DA4-395F-46C8-E040-BB89AD437C19","latestVersionIndicator":"Yes","beginDate":"2009-03-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-03-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"657C1DA4-3978-46C8-E040-BB89AD437C19","beginDate":"2009-03-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-03-19","modifiedBy":"ONEDATA","dateModified":"2009-03-19","deletedIndicator":"No"},{"value":"Non-Papillary","valueDescription":"Negation Papillary","ValueMeaning":{"publicId":"3165471","version":"1","preferredName":"Negation Papillary","longName":"3165471","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: of or relating to or resembling papilla.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Papillary","conceptCode":"C14166","definition":"Of or relating to or resembling papilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"96D7AA2D-09FF-EB1F-E040-BB89AD436E93","latestVersionIndicator":"Yes","beginDate":"2010-12-07","endDate":null,"createdBy":"WHITES","dateCreated":"2010-12-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"96D7AA2D-0A18-EB1F-E040-BB89AD436E93","beginDate":"2010-12-07","endDate":null,"createdBy":"WHITES","dateCreated":"2010-12-07","modifiedBy":"ONEDATA","dateModified":"2010-12-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435030","version":"1","preferredName":"NCI Administrative Concept","preferredDefinition":"Conceptual entities required by NCI operations and systems. Includes administrative, financial, organizational and quasi-scientific concepts required for NCI operations and systems. ","longName":"C28389","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07432182-1611-25E9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"56935A78-015A-3B03-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-10","endDate":null,"createdBy":"UMLLOADER_CATISSUE","dateCreated":"2008-09-10","modifiedBy":"KUMMEROA","dateModified":"2023-08-28","changeDescription":"9/28/10 Released for use in caTissue Suite version 1.1 and/or 1.2 per owners direction; added ref to PathAnnotation_SCG CSI","administrativeNotes":"2023.8.28 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"2919341","version":"1.1","longName":"caTissue_Suite1_1","context":"NCIP","ClassificationSchemeItems":[{"publicId":"10000411","version":"1","longName":"edu.wustl.catissuecore.domain.PathAnnotation_Specimen","context":"NCIP"}]},{"publicId":"2919341","version":"1.2","longName":"caTissue_Suite1_2","context":"NCIP","ClassificationSchemeItems":[{"publicId":"10000412","version":"1","longName":"edu.wustl.catissuecore.domain.PathAnnotation_Specimen","context":"NCIP"}]},{"publicId":"3787498","version":"1","longName":"TCGA 2.6 by Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3787505","version":"1","longName":"HNSC","context":"NCIP"},{"publicId":"3787508","version":"1","longName":"KIRP","context":"NCIP"},{"publicId":"3787513","version":"1","longName":"LUSC","context":"NCIP"},{"publicId":"3787516","version":"1","longName":"PRAD","context":"NCIP"},{"publicId":"3787502","version":"1","longName":"CESC","context":"NCIP"},{"publicId":"3787503","version":"1","longName":"COAD","context":"NCIP"},{"publicId":"3787506","version":"1","longName":"KICH","context":"NCIP"},{"publicId":"3787507","version":"1","longName":"KIRC","context":"NCIP"},{"publicId":"3787499","version":"1","longName":"BLCA","context":"NCIP"},{"publicId":"3787500","version":"1","longName":"BRCA","context":"NCIP"},{"publicId":"3787510","version":"1","longName":"LGG","context":"NCIP"},{"publicId":"3787509","version":"1","longName":"LAML","context":"NCIP"},{"publicId":"3787511","version":"1","longName":"LIHC","context":"NCIP"},{"publicId":"3787519","version":"1","longName":"SKCM","context":"NCIP"},{"publicId":"3787512","version":"1","longName":"LUAD","context":"NCIP"},{"publicId":"3787517","version":"1","longName":"READ","context":"NCIP"},{"publicId":"3787518","version":"1","longName":"SARC","context":"NCIP"},{"publicId":"3787520","version":"1","longName":"STAD","context":"NCIP"},{"publicId":"3787522","version":"1","longName":"UCEC","context":"NCIP"},{"publicId":"3787521","version":"1","longName":"THCA","context":"NCIP"},{"publicId":"3787515","version":"1","longName":"PAAD","context":"NCIP"}]}],"AlternateNames":[{"name":"SpecimenHistologicType:type","type":"UML Class:UML Attr","context":"NCIP"},{"name":"edu.wustl.catissuecore.domain.PathAnnotation_Specimen.SpecimenHistologicType.type","type":"UML Qualified Attr","context":"NCIP"},{"name":"Diagnosis Subtype","type":"TCGA_Name","context":"NCIP"},{"name":"diagnosis_subtype","type":"TCGA_XML_Name","context":"NCIP"}],"ReferenceDocuments":[{"name":"Data Element Specimen Histologic Type Type HistologicType does not have Preferred Question Text","type":"Preferred Question Text","description":"Data Element Specimen Histologic Type Type HistologicType does not have Preferred Question Text","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5692A8BC-AD72-1A7F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-10","endDate":null,"createdBy":"UMLLOADER_CATISSUE","dateCreated":"2008-09-10","modifiedBy":"TSESU","dateModified":"2018-07-16","changeDescription":"9/28/10 Released for use in caTissue Suite version 1.1 and/or 1.2 per owners direction","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}